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Preface 
The work presented in this Thesis is derived from my Ph.D. research, made possible 
primarily by the Ph.D. fellowship ref. SFRH/BD/80483/2011, from Fundação para a Ciência 
e a Tecnologia (FCT), Ministério da Ciência, Tecnologia e Ensino Superior (MCTES), Portugal. 
This study, carried out between 2012 and 2016, was integrated in the Ph.D. program of 
Centro Académico de Medicina de Lisboa (CAML), which is shared between Instituto de 
Medicina Molecular (IMM, Lisbon, Portugal), Faculdade de Medicina da Universidade de 
Lisboa (FMUL, Lisbon, Portugal) and Hospital Santa Maria, Centro Hospitalar Lisboa Norte 
(HSM-CHLN, Lisbon, Portugal). The work took place at the Angiogenesis Lab, at Centro 
Cardiovascular da Universidade de Lisboa (CCUL), under the supervision of Prof. Susana 
Constantino (CCUL/FMUL).  
 
This thesis is constituted by five chapters, which are preceded by a summary, both in 
Portuguese and in English. Chapter I consists of a general introduction to blood vessels, 
with particular emphasis on the angiogenic process, approached from the early embryonic 
development to adulthood, in physiology and pathology, arteriogenesis and postnatal 
neovascularization. A brief overview about the cellular and molecular effects of ionizing 
radiation is also presented. Chapter II specifically indicates the main objectives of the 
research proposal that led to the work presented in this thesis. Chapter III and IV include 
the experimental work developed through the research project. Chapter III, Low-dose 
ionizing radiation induces therapeutic neovascularization in a pre-clinical model of 
hindlimb ischemia, includes already published work (presented in word format) in 
Cardiovascular Research journal. Chapter IV, Low-dose ionizing radiation promotes 
neovascularization in experimentally induced diabetic mice subjected to hindlimb 
ischemia, includes results from ongoing work that is currently being developed in our lab 
and has not yet been published. Both results chapters include an abstract, a specific 
introduction, the results obtained in the work developed, and a focused discussion, as well 
as the methods and the references. In Chapter V, conclusions are integrated and discussed, 
generating new testable hypotheses which comprise the foreseen future directions of our 
research in this field.
Preface 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As opiniões expressas nesta publicação são da exclusiva responsabilidade do 
seu autor. 
 
 
A impressão desta Tese foi aprovada pelo Conselho Científico da Faculdade 
de Medicina de Lisboa em reunião de 18 de Julho de 2017. 
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Resumo 
O sistema circulatório ou cardiovascular é formado pelo coração e vasos sanguíneos e a sua 
função é levar oxigénio e nutrientes aos órgãos e tecidos do corpo. A doença 
cardiovascular, de que é exemplo a doença arterial periférica (DAP) é uma das principais 
causas de mortalidade e morbilidade na população mundial. Estima-se que mais de 25 
milhões de pessoas na Europa e nos Estados Unidos apresentem DAP, e a sua incidência 
tende a aumentar. Importantes fatores de risco para a DAP são a diabetes, tabagismo, 
hipertensão e dislipidemia. A DAP caracteriza-se por uma obstrução do lúmen arterial, 
resultando num défice de fluxo sanguíneo aos tecidos cuja principal consequência é a 
presença de sintomas característicos de isquemia. A manifestação mais frequente de DAP 
é a claudicação intermitente, que é caracterizada por desconforto muscular no membro 
inferior, produzido pelo exercício, e que alivia com o repouso. A claudicação tem um 
impacto negativo na qualidade de vida dos doentes, quer a nível profissional, quer 
interferindo com as suas atividades sociais. A isquemia crítica dos membros inferiores é a 
manifestação clínica mais grave da DAP, que descreve doentes com dor em repouso ou 
com lesões tróficas cutâneas, sejam elas úlceras ou gangrena. Aproximadamente 1% dos 
doentes com DAP apresentam o estado avançado da doença. As limitações dos 
procedimentos de revascularização, resultantes da extensão e distribuição anatómica da 
doença arterial, e do tratamento farmacológico, são bem conhecidas. Assim, a amputação 
surge como última alternativa terapêutica, apesar das taxas de morbilidade e mortalidade 
associadas. Na última década vários estudos têm vindo a ser desenvolvidos com o objetivo 
de encontrar tratamentos alternativos, incluindo a angiogénese terapêutica.  
A angiogénese terapêutica, a qual pode ser alcançada através da administração local de 
fatores de crescimento pró-angiogénicos na forma de proteína recombinante ou de células 
progenitoras endoteliais (CEPs) ou mesmo recorrendo à terapia génica, oferece uma 
possibilidade de recuperação para estes pacientes. Apesar dos estudos pré-clínicos e de 
alguns ensaios clínicos em fase I/II mostrarem-se bastante promissores, a progressão 
desses ensaios clínicos para terapias angiogénicas não têm revelado um efeito benéfico em 
doentes com isquemia crítica dos membros inferiores. Também o pouco conhecimento 
sobre os agentes angiogénicos envolvidos, nomeadamente a dose, a frequência e o método 
de administração têm contribuído para o fracasso dos ensaios clínicos.  
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No passado, o nosso grupo de investigação demonstrou que baixas doses de radiação 
ionizante (BDRI) promovem angiogénese durante o desenvolvimento embrionário e no 
processo de regeneração da barbatana caudal do peixe zebra. Assim, de acordo com os 
nossos resultados as BDRI induzem angiogénese in vivo, mas não existe prova de que 
produzam angiogénese terapêutica em doentes com doença isquémica, sendo este o 
propósito deste trabalho de doutoramento. Assim, o presente trabalho tem como objetivo: 
1) identificar os mecanismos celulares e moleculares pelos quais as BDIR poderão 
promover angiogénese terapêutica;  
2) avaliar se as BDRI promovem a vascularização pós-natal pelo aumento de CEPs 
em circulação e sua incorporação em locais de neovascularização nos tecidos 
isquémicos; 
3) demonstrar que as BDRI promovem neovascularização num modelo 
experimental de diabetes.    
Um modelo animal de isquémia foi desenvolvido usando fêmeas de ratinhos C57BL/6 e 
recorrendo a várias técnicas de biologia celular e molecular, nomeadamente RT-PCR, 
imunohistoquímica, imunofluorescência, citometria de fluxo, ELISA, microscopia de 
microdissecção a laser e diafanização. 
 
Neste estudo, após a indução de isquémia unilateral, os ratinhos C57BL/6 foram irradiados 
ou não com 0.3 Gy, durante quatro dias consecutivos.  
Os resultados demonstraram que as BDRI, aumentam significativamente a perfusão 
sanguínea no membro inferior do ratinho sujeito a isquémia, assim como a densidade 
capilar e a formação de colaterais. Foi também avaliada a vasculatura no membro inferior 
contralateral que apesar de irradiado não foi sujeito a isquémia. Neste caso particular, nem 
a densidade capilar, nem a formação de colaterais registaram alterações quando 
comparadas com animais não irradiados. Estas observações sugerem que em condições 
não patológicas as BDRI não têm efeito na vascularização.  
De forma a validar os mecanismos moleculares no nosso modelo isquémico, foram 
selecionados os melhores candidatos associados a uma resposta pró-angiogénica a partir 
de uma análise de expressão gênica por microarrays. Os nossos resultados mostraram que 
a expressão de vários genes pró-angiogénicos nomeadamente, Vegfr2, Vegfr1, Fgf2, 
Angpt2, Pdgfc, Tgfb2, Hgf e Met está induzida em células endoteliais isoladas de músculos 
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de ratinhos sujeitos a isquémia e comparadas com a expressão em células endoteliais 
isoladas dos músculos não isquémicos contralaterais. Desta forma, as BDRI sugerem 
conferir uma resposta pró-angiogénica após indução de isquémia.  
Neste trabalho foi também demonstrado que as BDRI aumentam significativamente tanto 
a concentração de VEGF, PIGF e G-CSF como de CEPs em circulação e medeiam a 
incorporação destas células nos músculos isquémicos.   
Este trabalho revela ainda que não existe diferença de morbilidade nem de mortalidade 
em ratinhos irradiados quando comparados com ratinhos não irradiados, sendo eles 
acompanhados durante 52 semanas após exposição a BDRI. 
 
Para complementar este trabalho e sendo a diabetes um importante fator de risco no 
contexto da DAP, foi observado que em resposta à indução de isquémia as BDRI, 
administradas durante quatro dias consecutivos, aumentam significativamente a perfusão 
sanguínea, a densidade capilar e a formação de colaterais num modelo experimental 
diabético. No entanto estes dados resultam de um estudo preliminar, sendo crucial o 
aumento do número de animais.  
 
Em conclusão, o presente trabalho demonstra que BDIR induzem angiogénese terapêutica 
num modelo experimental de isquémia do membro inferior. Este trabalho é relevante pois 
propõe o uso de BDIR como uma estratégia inovadora e não invasiva no tratamento da 
isquémia crítica do membro inferior. 
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Abstract 
Peripheral arterial disease (PAD) is mainly caused by an obstructive artherosclerosis, which 
results in a mismatch between oxygen supply and demand. Diabetes is an important risk 
factor for PAD and it is present in almost 50% of the patients with limb ischemia. Critical 
limb ischemia (CLI) is the end stage of PAD, being characterized by severe obstruction of 
blood flow to the affected extremity, which results in ischemic rest pain, ulcers or gangrene. 
Despite substantial evidence of their efficacy in preclinical studies, as well as some 
promising phase I/II clinical trials, larger randomized clinical trials on angiogenic therapies 
for CLI have been unsatisfactory. 
Here, we investigated the ability of low-dose ionizing radiation (LDIR) to stimulate 
therapeutic neovascularization, in murine models, in a context of hindlimb ischemia (HLI), 
conjugated or not with diabetes. 
We demonstrate that 0.3 Gy, administered for four consecutive days, significantly improves 
blood perfusion in the murine ischemic limb by stimulating angiogenesis and 
arteriogenesis, as assessed by laser Doppler flow, capillary density and collateral vessel 
formation. LDIR significantly increased the circulating levels of VEGF, PlGF and G-CSF, as 
well as the number of circulating endothelial progenitor cells (EPCs), mediating their 
incorporation into ischemic muscles. These effects were dependent upon LDIR exposition 
on the ischemic niche (thigh and shank regions). In irradiated ischemic muscles, these 
effects were independent of the recruitment of monocytes and macrophages. Also, the 
vasculature in an irradiated non-ischemic bed was not affected and after 52-week LDIR 
exposure no differences in the incidence of morbidity and mortality were seen. 
Additionally, in diabetic mice, our data suggest that 0.3 Gy applied during four consecutive 
days significantly promote blood perfusion, capillary and collateral vessel densities in 
response to HLI induction. These findings disclose an innovative and non-invasive strategy 
to induce therapeutic angiogenesis in a murine model of severe HLI, emerging as a novel 
approach in the treatment of CLI. 
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LDIR   low-doses ionizing radiation  
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MAPK   mitogen-activated protein kinase 
MCP1   monocyte chemoattractant protein 1  
MET   hepatocyte growth factor receptor 
MMPs   matrix metalloproteinases  
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NOS   nitric oxide synthase 
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PAD   peripheral arterial disease  
PB-MNCs  peripheral blood-derived mononuclear cells  
PCA   principal component analysis  
PDGF   platelet-derived growth factor  
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PECAM-1  platelet endothelial cell adhesion molecule 1 
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RT‐PCR  real-time polymerase chain reaction 
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SDF-1   cell-derived factor-1  
SMCs   smooth muscle cells  
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TACT   Therapeutic Angiogenesis Using Cell Transplantation  
TGFβ   transforming growth factor β 
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TNFα   tumor necrosis factor α 
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1. Blood vessels: Structure and Function  
Contrarily to primitive and smaller organisms, the complex body architecture of 
vertebrates requires an efficient circulatory system, able to distribute oxygen and nutrients 
to tissues and remove carbon dioxide and other metabolic waste products throughout the 
body. 
The circulatory system carries out two main networks: the blood-vascular and the 
lymphatic systems, both formed by endothelial cells (EC). The cardiovascular system allows 
blood to circulate and transport nutrients, oxygen, carbon dioxide and other molecules 
throughout all cells in the body1, while the lymphatic system drains extravassed fluid, the 
lymph, from the extracellular space and returns it into the venous circulation. The 
lymphatic vasculature is also essential for the immune defense, since any foreign material 
present in the lymph is filtered through the chain of lymph nodes2. Both networks are 
essential for homeostasis of a healthy organism, and their malformation or dysfunction 
contributes to many diseases1. 
Blood vessels are divided into three main groups: arteries, veins, and capillaries3. Briefly, 
blood full of oxygen and nutrients is pumped from the heart to the tissues, through the 
arteries that ramify into smaller arterioles and into capillary beds, while blood enriched in 
carbon dioxide and waste returns to the heart through venules and veins1. 
Arteries and veins are further divided according to their caliber, into large, medium and 
small blood vessels. The microvasculature composed of the smallest vessels (arterioles, 
venules and capillaries) is a very dynamic and complex system, capable of constant change, 
while the larger blood vessels are more permanent structures with reduced plasticity3. 
Capillaries, the most abundant vessels in our body, are also one of the most important 
vessels of the cardiovascular system, since their thin walls allow the exchange of oxygen 
and nutrients between blood and tissues3. Capillaries are composed of endothelial cells 
surrounded by basement membrane and a sparse layer of pericytes embedded within the 
EC basement membrane. Pericytes, due to their contractile fibers, possess a cell body with 
prominent nucleus and a small content of cytoplasm. They are functionally significant, since 
when vessels lose pericytes, they become hemorrhagic and hyper dilated, leading to 
conditions such as edema, diabetic retinopathy, and even embryonic lethality4. Capillaries 
in different tissues exhibit different cellular morphology, associated with distinct levels of 
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permeability (Figure 1): (a) continuous capillaries, characterized by an uninterrupted 
endothelium and a continuous basement membrane, that exist, for instance, in muscle, 
lung or the nervous system; (b) fenestrated capillaries, characterized by a continuous 
basement membrane with fenestrae or pores in the endothelium that allow the rapid 
passage of macromolecules and exist, for example, in the kidney, intestines or endocrine 
glands and (c) discontinuous capillaries, characterized by large openings in the 
endothelium and a discontinuous or absent basement membrane that exist, for instance, 
in the liver and spleen5.  
 
 
Figure 1 - Capillary wall morphology. (a) Continuous capillaries have no openings in their wall and 
are lined continuously with the EC body. (b) Fenestrated capillaries have small openings, called 
fenestrae that are covered by a small, non-membranous, permeable diaphragm and allow the rapid 
passage of macromolecules. The basement membrane of ECs is continuous over the fenestrae. (c) 
Discontinuous capillaries have a large lumen, many fenestrations with no diaphragm and a 
discontinuous or absent basal lamina. Adapted from reference5. 
 
In contrast, the walls of larger vessels (arteries and veins) have three specialized layers 
(Figure 2). The tunica intima consists of an endothelium, a basement membrane and an 
internal elastic layer. The tunica media is composed of a thick layer of smooth muscle cells 
(SMCs) with reticular fibers, elastin and proteoglycans and external elastic lamina, while 
the tunica adventitia consists of connective tissue with both elastic and collagenous fibers 
and external elastic lamina5,6. Arterioles and venules have an increased coverage of mural 
cells when compared to capillaries. 
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The advential layer has its own blood supply, known as vasa vasorum. SMCs and elastic 
laminae contribute to the vessel tone and mediate the control of vessel diameter and blood 
flow. Although the walls of arteries and veins are composed of these same layers, they 
present some differences as a result of the pressure and direction of the blood flow. 
Arteries are more robust, with a strong elastic vessel wall to cope with the high arterial 
blood pressure downstream of the heart. Since veins conduct blood back to the heart, 
blood flows with a lower pressure in veins and consequently their wall is thinner than the 
one of arteries. Veins have additional semi-lunar valves, which prevent the blood from 
flowing backwards5.  
 
 
Figure 2 - Morphology and wall composition of large blood vessels. Adapted from reference7.  
 
1.1. Endothelial Cell Specification 
Although arteries and veins are both formed from primitive blood vessels, different 
hemodynamic changes and physiology lead to their distinct morphology and physiology 
factors, in a process known as arteriovenous differentiation1,2,8. Hemodynamic forces such 
as blood flow rate, direction, and pressure are key factors driving the differentiation of 
vessels into arteries and veins. However, studies have demonstrated that arteries and veins 
possess distinct molecular identities from a very early stage, suggesting that genetics have 
a critical role in dictating arterial/venous fate9. Although the molecular processes 
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underlying arteriovenous differentiation are not fully understood, increasing evidence 
suggests that this process is regulated by the concerted action of different molecules.  
The first discovered specific markers that distinguish arteries from veins were two 
members of the Eph-Ephrin subclass of receptor tyrosine kinases, ephrinB2 and EphB49. 
EphrinB2 is a transmembrane ligand and is specifically expressed in endothelial precursors 
that produce arteries, whereas Ephb4, the receptor for Ephrin B2, is found preferentially in 
veins10. Mice deficient in Ephrin B2 and Ephb4 have similar defects in the remodeling of 
primary capillary vessels into a mature vascular network8.  
It is known that Notch pathway is directly involved in the differentiation of the arterial 
branch1. In mice, the receptors Notch1 and Notch2 and the ligands Jagged1, Jagged2 and 
delta‐like‐4 (DLL4) are all expressed in arterial but not in venous ECs. Notch4-/- and Notch1-
/- mice exhibit abnormal vascular development, whereas Dll4-/- mice are not viable, 
presenting severe vascular defects and showing reduced EphrinB2 expression and 
increased EphB4 expression, consistent with a failure in arterial differentiation. These data 
suggest that Notch activity is important for the promotion of arterial cell fate9,11. Upstream 
from Notch pathway are Foxc1 and Foxc2 (forkhead C1 and C2) that control arterial 
specification by regulating the expression of the Notch ligand Dll4. Mice with inactivated 
Foxc1 and Foxc2 develop arterial-venous malformations10. 
Additionally, COUP-TFII (chicken ovalbumin upstream promoter transcription factor II) is 
specifically expressed in venous endothelium. COUP-TFII mutant mice show ectopic 
expression of arterial markers such as neuropilin 1 (NRP1), Notch1 and EphrinB2 in veins. 
These studies suggest that COUP-TFII is a crucial regulator of venous cell fate by inhibiting 
the expression of NRP1 and Notch signaling8,12. 
The expansion of larger arteries and veins occurs by acquisition of additional layers of mural 
cells, extracellular matrix (ECM) and elastic laminae to provide the required viscoelastic 
properties. Homotypic and heterotypic junctions facilitate cell-to-cell communication and 
regulate vessel permeability. Vascular endothelial cadherin is an important component of 
EC-EC junctions, whereas neural cadherin facilitates EC-mural cell communication. Gap 
junctions (made of connexins) also facilitate communication between ECs and between ECs 
and perivascular cells. Tight junctions (formed by occludins, claudins and zona occludens) 
contribute to the blood tissue barrier in the brain and retinal capillaries6. 
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2. Vasculogenesis 
Vasculogenesis is a fundamental process by which new blood vessels are formed, 
characterized by the differentiation of precursor cells into endothelial cells and the de novo 
formation of a vascular network. 
 
2.1. Vasculogenesis during embryo development 
The development of the vascular system is one of the earliest events in organogenesis13. In 
vertebrates, one of the mechanisms by which the vascular development proceeds is via 
vasculogenesis, the process of de novo blood formation, characterized by the formation of 
vessels directly from angioblastic precursors14. 
In the early phase of vasculogenesis, hemangioblasts undergo their first critical steps of 
differentiation within the blood islands, being committed to differentiate into angioblasts 
and primitive haematopoietic cells. The angioblasts aggregate in the periphery and the 
hematopoietic precursors accumulate at the center of the blood islands in the yolk sac and 
embryo15,16. The angioblasts migrate to discrete locations, differentiate in situ and 
assemble into solid endothelial cords, later forming a plexus with endocardial tubes13. 
Vascular endothelial growth factor (VEGF) and their receptors, vascular endothelial growth 
factor receptor 1 and 2 (VEGFR1 and VEGFR2), are key players in embryonic vessel 
formation. Particularly, VEGFA is required for the chemotaxis and differentiation of 
endothelial precursor cells, EC proliferation and angiogenic remodeling1. Genetic studies 
show that the deficiency in one of these VEGF/VEGFR molecules is lethal in mice, due to 
failed development of the vasculature2,16. The lethality resulting from the loss of a single 
allele is indicative of a dependent regulation of embryonic vessel development by VEGFA2. 
The existence of a precursor for these cells types (haemangioblast) is suggested by defects 
in both the haematopoietic and angioblastic lineages of embryos lacking VEGFR2. 
Moreover, in the absence of the VEGFR1 mice produce angioblasts but their assembly into 
functional blood vessels is impaired17. 
 
2.2. Postnatal Vasculogenesis  
Until the late 1990s, it was generally accepted that after birth, new blood vessels were 
developed only by angiogenesis. However, new findings indicate that vasculogenesis is not 
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restricted to early embryogenesis18. Asahara et al., pioneer in the scientific field of adult 
vasculogenesis, isolated mononuclear cells from adult peripheral blood and found that 
those cells had the same characteristics as the embryonic angioblasts, contributing to the 
revascularization of the ischemic tissue19. These cells were termed “endothelial progenitor 
cells” (EPCs). Thus, a new concept, describing postnatal neovascularization as a 
combination of vasculogenesis and angiogenesis, in which EPCs play a crucial role, 
emerged18. 
 
2.2.1. EPCs phenotypic identification and characterization 
The identification of EPCs can be based on their cellular origin, isolation methods and 
surface marker expression20. Although the analysis of cell surface markers is currently the 
most used methodology21, EPCs identification is controversial, since there is no unique 
protein marker that defines them22. The analyzed markers are usually shared with cells 
from hematopoietic lineage and mature ECs23. Therefore, EPCs combine stem cell markers, 
such as CD133, c-kit and Sca-1 and endothelial markers, such as VEGFR2, CD31, VE-cadherin 
and von Willebrand factor20,24. CD34 represents a link between precursor and mature cells, 
since it is expressed in both cell types. On the other hand, CD133 allows the distinction 
between progenitor and mature cells, since it is not present on mature ECs22. 
Beyond the controversy about the phenotypic identification of EPCs, the heterogeneity of 
cultured cells has also been a concern. Many studies reported EPCs after using different 
sources of the cells or method for culture22,25-27. For instance, human CD34+ cells isolated 
from peripheral blood, umbilical cord blood or bone marrow can all differentiate into ECs. 
Moreover, studies show that when total mononuclear cells, isolated from peripheral blood, 
are cultured in vitro, two types of cell populations that appear sequentially can be 
observed26. The first population, “Early EPCs”, comes after 4-7 days of plating on 
fibronectin-coated surface with the addition of endothelial growth media, as spindle-
shaped cells. “Early EPCs” gradually loose CD45 and CD31 expression and gain low-level 
expression of VEGFR2 and VE-Cadherin. However, they lose this low-level expression of 
VEGFR2 and VE-cadherin after 3 weeks, dying after that26. These cells play a role in 
vasculogenesis by secreting large quantities of angiogenic factors, which act through 
paracrine mechanisms28. On the other hand, when blood-derived mononuclear cells are 
maintained in culture for 2-3 weeks “late EPCs” can be observed22. “Late EPCs” have a 
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higher and longer sustained expression of VEGFR2 and VE-cadherin26, much higher 
proliferation potential and are able to differentiate into ECs and promote vascular tube 
formation22. Thus, “late EPCs” enhance neovasculogenesis, by providing a sufficient 
number of ECs based on their high proliferation potency26. These two type of cells have the 
ability to absorb acetylated low-density lipoprotein and bind lectin Ulex europaeus 
agglutinin I29. Despite such differences in genetic and functional in vitro aspects, they 
equally contribute to neovasculogenesis26. 
 
2.2.2. Mobilization and Recruitment of EPCs 
Under physiological conditions, levels of EPCs in the peripheral circulation are low and 
these cells reside in the bone marrow niche in a quiescent state30. The mobilization of EPCs 
from the bone marrow into the peripheral circulation is promoted by several growth 
factors, chemokines and cytokines which are produced in response to a physiological stress 
(tissue hypoxia and trauma) (Figure 3)31. 
One of the most important factors in EPCs mobilization is VEGF. When VEGF interacts with 
its receptor, VEGFR2, it activates nitric oxide synthase (NOS) in the bone marrow, which 
produces nitric oxide (NO), a key player for matrix metalloproteinase 9 (MMP) 9 activation. 
Activated MMP-9 contributes to the transformation of membrane-bound Kit ligand to a 
soluble form (sKitL) and consequently detaches EPCs from the bone marrow niche to the 
peripheral circulation28. 
Once in circulation, homing of EPCs is activated in response to chemokine gradients that 
are formed in the tissue undergoing active remodeling. The major chemokine that 
regulates activation and homing of EPCs is the stromal cell-derived factor1 (SDF1)32,33. In 
response to an ischemic stimulus, released SDF1 interacts with its receptor (CXCR4), and 
initiates, not only the mobilization of EPCs from bone marrow, but also their adhesion to 
ischemic areas. The SDF-1/CXCR4 interaction upregulates the P-selectin glycoprotein ligand 
1 (PSGL1) expression on the surface of EPCs, which is the major ligand of P-selectin. The 
binding contributes to the adhesion of EPCs to the sites of vessel damage and enhances 
their pro-angiogenic capacity. However, in the absence of injury, the effect of SDF1 is 
abolished. After homing into the injured vessel wall, EPCs will contribute to new vessel 
formation and remodeling, but the mechanism behind the functional activity of EPCs is still 
under investigation. Besides differentiating into ECs, EPCs also produce multiple paracrine 
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factors, such as VEGF, SDF1, hepatocyte growth factor (HGF), angiopoetin1 (ANGPT1), 
insulin-like growth factor 1, monocyte chemoattractant protein1 (MCP1) and platelet-
derived growth factor (PDGF). These factors can assist different cell types in promoting 
angiogenesis and tissue regeneration, reflecting the indirect contribution of EPCs to 
neovascularization34. 
EPCs are mobilized from bone marrow into the peripheral circulation and recruited into 
sites of vessel injury to participate in blood vessel formation, in both physiological and 
pathological conditions. However, the mechanisms of mobilization and recruitment are still 
incompletely understood and require further analysis. Nevertheless, several studies 
suggest that EPCs play a critical role in postnatal neovascularization and vascular 
homeostasis30. 
 
Figure 3 - EPCs mobilize in response to hypoxia induced by trauma or vascular injury. In normal 
homeostatic conditions, EPCs reside within a stem cell niche in the bone marrow. Peripheral tissue 
hypoxia under trauma, wound healing or vascular injury conditions results in increased production 
of EPC-mobilizing chemokines and growth factors to a concentration greater than that in the bone 
marrow, causing EPC release and mobilization into the peripheral circulation. Once in circulation, 
EPCs respond to chemokine signaling in the tissues by undergoing active remodeling and homing 
to the injury site. Concomitantly, circulating progenitor cells, tissue-resident, and adipose-derived 
stem cells respond to the chemokine signaling, homing to the active tissue-remodeling site. 
Adapted from reference20.  
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3. Arteriogenesis 
Arteriogenesis, defined as the formation of mature arteries from pre-existing arterioles 
after an arterial occlusion, needs to be activated to confer proper tissue function35 (Figure 
4). 
 
Figure 4 - Arteriogenesis. Arterial occlusion induces a pressure gradient followed by a redistribution 
of perfusion, an increase in collateral flow and a subsequent outgrowth of the collateral arteriole. 
Adapted from reference36. 
 
The driving force for arteriogenesis is altered fluid shear stress (FSS), which appears within 
the collateral arteriole after a blood flow increase. However, the large pressure difference 
in the pre-existing arterioles connecting upstream with downstream branches, relative to 
the point of occlusion, also contributes to initiate a complex cascade of molecular and 
cellular events leading to increased vessel lumen and wall thickness37. The primary 
physiological response to FSS is the activation of ECs in the collateral wall. After an arterial 
occlusion, the ECs of collateral vessels appear swollen, as opposed to the completely flat 
inner surface of normal arteries38. The endothelial activation is indicated by several 
processes that condition for the attraction of circulating cells: upregulated genes that 
encode for chemoattractant or activated cytokines, including growth factors or adhesion 
molecules37. Thus, changes in the expression and conformation of adhesion molecules 
converts the collateral endothelium from a quiescent vessel layer with very low adhesion 
tendency into a highly activated one, which is now supporting attraction, adhesion and 
invasion of leukocytes37. Also, several molecules involved in cell proliferation and migration 
were found up-regulated, including MMP2, MMP9, urokinase-type plasminogen activator 
(uPA), focal adhesion kinase (FAK) and integrins (α5β1 and αvβ3)38. Moreover, after an 
arterial obstruction, the altered FSS induces at least two signaling pathways: (1) the 
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attraction, adhesion and invasion of monocytes that are required for structural remodeling 
and (2) the pathway that causes ECs and SMCs to enter the cell cycle, leading to 
proliferation. Thus, in response to altered FSS, NO and VEGF are induced and, together with 
calcium-activated ion channels, interfere with osmotic regulation of the endothelium38,39. 
This occurs along with monocyte adhesion, since the activated endothelium produces 
MCP1, leading to the recruitment of monocytes to the sites of proliferation40. After the 
initial monocyte-endothelium interaction, which is mediated by several selectins, the tight 
monocyte adhesion to the endothelium is triggered by macrophage-1 antigen (Mac1) and 
lymphocyte function-associated antigen (LFA). These integrins interact with their 
corresponding adhesion molecules (intercellular adhesion molecule 1 and 2 (ICAM1), 
(ICAM2) and vascular cell adhesion molecule 1 (VCAM1), (respectively) on the endothelial 
cell surface41. After adhesion, migration into deeper parts of the collateral wall and 
surrounding areas can be observed. During migration, monocytes should overcome 
barriers, like the internal elastic lamina and ECM. However, as monocytes are producers of 
proteases, such as MMPs and uPA, they enable the proteolytic degradation of these 
barriers and could therefore create a gap by which monocytes could invade the vascular 
wall. At the same time, these events may also generate a proliferation signal for SMC37. 
Furthermore, lymphocytes (natural killer family, CD4 and CD8 cells) also play a role in 
arteriogenesis. Studies from Stephen Epstein´s group showed that in mice with a genetic 
deficiency in the T-cell marker CD4, arteriogenesis was inhibited in the hindlimb ischemia 
model, but could be rescued by an injection of purified CD4 positive cells. Additionally, the 
lack of CD4 positive T-cells led to a reduced inflammatory response in the same model 
including a consistent reduction in the number of monocytes37. As mentioned before, 
remodeling from a small pre-existing arteriole to a large collateral artery is facilitated by a 
complex cascade of processes. The signaling cascade uses the mitogen activated protein 
kinases with activation of the RAS-ERK- and the Rho pathway41. ECs mitosis precedes that 
of SMCs by a few hours and growth factors are released from monocytes such as MMPs, u-
PA and fibroblast growth factor 2 (FGF2) during that time38. Also, degradation of 
extracellular structures leads to the release of additional matrix-bound growth factors. The 
increase in cell mitosis in SMCs occurs together with a morphological change: their 
transformation from a contractile into a proliferative/synthetic phenotype. Elastin is 
present in the elastic lamina, preventing SMCs proliferation, but its degradation products 
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stimulate SMCs proliferation41. Subsequently, SMCs migrate and rearrange accordingly to 
the increasing vessel lumen and wall thickness. The controlled destruction of the vascular 
scaffolding paves the way for the expansion and outward growth of collateral vessels. 
Moreover, apoptosis of SMCs may facilitate the renewal of the vascular wall38. Finally, 
remodeling enters in a maturation state when both elastic lamina and ECM components 
are rearranged. In this process, laminin and collagen IV are crucial since they promote the 
differentiation and inhibit the proliferation of SMCs37.   
 
4. Angiogenesis  
After the formation of a primitive vascular plexus during vasculogenesis, the growth, 
expansion and remodeling of primitive vessels into a mature vascular network (including 
arteries, veins, and capillaries) is initiated. This process, named angiogenesis, occurs by 
intussusception, in which interstitial tissue columns are inserted into the lumen of pre-
existing vessels, inducing partition of the vessel lumen, or by sprouting of new vessels from 
the ends and sides of the pre-existing ones17,42-44. 
The sprouting angiogenesis is facilitated by hypoxia, which regulates the expression of 
several genes involved in vessel formation, patterning and maturation, such as NOS, VEGF 
and ANGPT26. The existing vessels dilate and become leaky in response to NO and VEGF, 
respectively. At the same time, redistribution of intercellular adhesion molecules (platelet 
endothelial cell adhesion molecule 1(PECAM1), vascular endothelial cadherin (VE 
cadherin)) and alteration in cell membrane structure occur16. Consequently, the 
extracellular matrix ECM dissolves in response to activation of MMPs (MMP2, MMP3 and 
MMP9) and suppression of protease inhibitors. Degradation of ECM also results in the 
release of growth factors, including FGF2, VEGF and insulin-like growth factor, which 
otherwise remain stored within the matrix. As the physical barriers are dissolved, ECs can 
migrate to distant sites, through interactions between integrins (αvβ3 and α5β1) and the 
matrix proteins, and proliferate in response to VEGF and other endothelial mitogens 
(ANGPTs, FGFs and PDGF)6,16.  
The different steps of angiogenic process are explained in Figure 5. Briefly, the ECs, also 
known as “tip cells”, become selected to lead the tip in the presence of factors such as: 
VEGF receptors, NRPs and NOTCH ligands. The neighbors of the “tip cell” assume positions 
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as “stalk cells”, which divide to support sprout elongation and establish the lumen3,44,45. At 
this point, the vessel sprouting remodels into a highly organized vascular network of larger 
vessels ramifying into smaller ones160. Then, the maturation process begins, described as 
the stepwise transition from an actively growing vascular bed to a quiescent functional 
network. This process involves the suppression of endothelial proliferation and sprouting, 
and the stabilization of existing vascular tubes through the recruitment of mural cells. 
Pericytes establish direct cell-cell contact with ECs in capillaries and immature vessels, 
whereas SMCs cover large diameter vessels (arteries and veins) and are separated from ECs 
by a matrix1. During this process, the pericytes and SMCs contribute to the deposition of 
ECM. This is critical for normal vessel growth and maintenance by providing the solid 
scaffold through which new vessels may migrate and store growth factors and pro-enzymes 
involved in vessel development. Thus, the recruitment of these mural cells is crucial for the 
maturation and stability of the new vasculature44.  
The regulation of the angiogenic process involves at least four molecular pathways: (1) 
PDGF/platelet-derived growth factor receptor (PDGFR); (2) ANGPT1/Tie2; (3) Transforming 
growth factor β (TGFβ) and (4) Sphingosine 1 phosphatase receptor (S1PR) signaling. The 
PDGF/PDGFR signaling is an important regulator of this process. PDGFβ is secreted by ECs 
in response to VEGF, recruiting pericytes and SMC and allowing their proliferation and 
migration during vascular maturation6. Pdgf mutations leads to poorly covered vessels with 
excessive endothelial sprouting, microaneurysms, leakage and haemorrhaging1. 
Also, critical for vessel formation and stability are ANGPT1 and ANGPT2 and their Tie 
receptors. The Tie2 receptor is expressed in ECs and is stimulated by ANGPT1 and ANGPT2, 
expressed by mural cells and ECs, respectively1,46. ANGPT1 stabilizes nascent vessels and 
makes them leak-resistant through the communication between ECs and mural cells6. In 
agreement with this, mouse mutants for Tie2 or ANGPT1 have similar behaviors, presenting 
severe vascular defects, and are unable to recruit pericytes47. The role of ANGPT2 is 
dependent on the presence or absence of VEGF. When VEGF is present, ANGPT2 promotes 
blood vessel growth and sprouting; the absence of VEGF leads to endothelial cell death and 
vessel regression48,49. 
Additionally, TGFβ1 is also involved in the stabilization of immature vasculature. It is a 
multifunctional cytokine that promotes the maturation of vessels through the stimulation 
of SMC differentiation and ECM deposition, while inhibiting ECs proliferation and 
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migration. TGFβ1 is expressed in ECs and mural cells and can be either pro or anti-
angiogenic, depending on context and concentration 6. Loss of function of TGFβR2 in mice 
causes vessel fragility due to impaired mural cells development50. 
Also, S1PR signaling controls EC/mural cell interaction. Endothelial-derived S1P binds to G 
protein-coupled S1PRs and triggers cytoskeletal, adhesive and junctional changes, affecting 
cell migration, proliferation and survival. Disruption on S1PR1 or loss of both S1PR2 and 
S1PR3 in mice causes defective coverage of vascular SMCs50.  
In the end of the maturation process ECs acquire highly specialized characteristics to 
provide the functional needs within specific tissues and organs16. This process includes 
arterio-venous determination, formation of homotypic and heterotypic junctions and ECs 
differentiation to form organ-specific capillary structures6. 
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Figure 5 - Angiogenesis. (a) After stimulation with angiogenic factors, the quiescent vessel dilates 
and an EC tip cell is selected to ensure branch formation. Tip cell formation requires degradation of 
the basement membrane, pericyte detachment and loosening of endothelial cell junctions. 
Increased permeability permits extravasation of plasma proteins to deposit a provisional matrix 
layer, and proteases remodel the pre-existing interstitial matrix, all enabling cell migration. (b) Tip 
cells navigate in response to guidance signals and adhere to the ECM to migrate. Stalk cells behind 
the tip cell proliferate, elongate and form a lumen, and sprouts fuse to establish a perfused 
neovessel. Proliferating stalk cells attract pericytes and deposit basement membranes to become 
stabilized. (c) After fusion of neighboring branches, lumen formation allows perfusion of the 
neovessel, which resumes quiescence by the promotion of a phalanx phenotype, re-establishment 
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of junctions, deposition of basement membrane, maturation of pericytes and production of 
vascular maintenance signals. Adapted from reference45.  
 
4.1 Physiological Angiogenesis 
After birth, angiogenesis still contributes to organ growth, but once the new vessels are 
assembled, the ECs become notably resistant to exogenous factors and most blood vessels 
remain quiescent16,43. Accordingly, in adults and in physiological conditions, angiogenesis 
occurs only in specific situations, such as wound healing, regeneration of the endometrium 
during the menstrual cycle or in the placenta during pregnancy6,51. 
Quiescent ECs retain their remarkable ability to divide rapidly in response to a physiological 
stimulus, such as hypoxia, low pH or shear stress, and therefore influence the formation, 
maturation and remodeling of small and large vessels6,51. Thus, in physiological situations, 
it is reasonable to assume that molecules involved in vessel formation and maturation 
during embryonic development are also involved in the postnatal period, but their precise 
role is not yet known because most knockout mice die pre- or perinatally6. 
 
4.1.1 Angiogenic Regulators 
In multicellular organisms, the process of angiogenesis is regulated by a complex and tight 
balance between pro- and anti-angiogenic molecules43. Physiologically, the body controls 
angiogenesis through a series of “on” and “off” regulatory switches. The main “on” 
switches are known as angiogenesis growth factors and the main “off” switches are known 
as endogenous angiogenesis inhibitors. A selective list of the main stimulators and 
inhibitors that take part in the angiogenic process is shown in Table 1 and some of these 
factors will be briefly detailed below 52.  
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Table 1 - List of the main angiogenic stimulators and inhibitors. Adapted from reference52. 
Angiogenic Stimulators Angiogenic Inhibitors 
Angiogenin Angioarrestin 
Angiopoietin-1 Angiostatin 
Fibroblast growth factors Endostatin 
Granulocyte colony-stimulating factor (G-CSF) Fibronectin fragment 
Hepatocyte growth factor Heparinases 
Interleukin-8 Interferon alpha/ beta/gamma 
Placental growth factor Interferon inducible protein 
Platelet-derived endothelial cell growth factor Interleukin-12 
Platelet-derived growth factor-BB Metalloproteinase inhibitors 
Pleiotrophin Plasminogen activator inhibitor 
Progranulin Retinoids 
Transforming growth factor alpha and beta Thrombospondin-1 
Tumor necrosis factor-alpha Vasculostatin 
Vascular endothelial growth factor Vasostatin 
 
Vascular Endothelial Growth Factor 
VEGF family consist of six members: VEGFA, also called VEGF, VEGFB, VEGFC, VEGFD, PIGF 
and virus VEGF (VEGFE)53. VEGF was the first identified and the most studied of the VEGF 
family members54. VEGF is expressed in different tissues including brain, kidney, liver, 
spleen and by many different cell types55. Several in vitro studies have shown that VEGF 
stimulates microvascular EC proliferation, enhancing migration and inhibiting apoptosis. 
Additionally, VEGF induces the growth of new capillaries from preexisting vasculature. In 
vivo studies also showed that VEGF regulates vascular permeability, which is important for 
the initiation of angiogenesis56-59. VEGF causes vasodilatation by inducing endothelial nitric 
oxide synthase and thus increasing NO production60, and it also plays a crucial role in 
several angiogenic processes, namely wound healing, ovulation, maintenance of blood 
pressure, menstruation and pregnancy61. In humans, VEGF is expressed in almost every 
solid tumors as well as in some hematological malignances62. 
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Different growth factors and cytokines such as PDGF, tumor necrosis factor α (TNFα), TGFβ 
and interleukin 1β (IL1β) induce transcription of VEGF mRNA, thus VEGF may function as a 
mediator for indirect action of angiogenic factors53. VEGF levels can also be regulated by 
tissue oxygen tension, since exposure to hypoxia induces VEGF expression. In contrast, 
normoxia downregulates VEGF production and even causes regression of some newly 
formed blood vessels63. 
The expression of VEGF has been shown to be associated with significant steps in 
angiogenesis and physiological vasculogenesis. According to this, several in vivo studies 
demonstrate that, in mice, deletion of the VEGF gene leads to embryonic death, resulting 
in vascular defects and cardiovascular abnormalities64.There are currently six isoforms of 
VEGF resulting from alternative splicing of a single gene (VEGF121, VEGF145, VEGF165, 
VEGF183, VEGF189 and VEGF206). Some of these isoforms remain associated with cells or 
membranes, while others are extracellularly released. Despite this difference, all of them 
have identical biological activities65,66. 
Two high affinity binding sites for VEGF have been identified on vascular endothelium: 
VEGFR1 (Flt1) and VEGFR2 (KDR or Flk1). An additional member of this family, VEGFR3 (Flt4) 
is not a receptor for VEGF but binds VEGFC and VEGFD55. All VEGF receptors have seven 
immunoglobulin domains in their extracellular part and an intracellular tyrosine kinase 
domain65. Also, all VEGF receptors are expressed in high levels during embryogenesis, and 
in adults VEGFR1 and VEGFR2 are mainly expressed in the blood vascular system, whereas 
VEGFR3 is restricted to the lymphatic endothelium67. Knockout mice for VEGFR1 or VEGFR2 
are embryonically lethal, being the blood vessels completely absent, which suggest that 
both receptors are essential for normal development of the embryonic vasculature68,69. 
Neuropilin, another receptor for VEGF, was primarily identified as a receptor for members 
of the collapsing/semaphoring family on neuronal cells, but it is also expressed on ECs. 
Neuropilin is an isoform specific receptor that binds to VEGF16565. 
VEGFR1 strongly interacts with VEGF, but this interaction plays a minor role in angiogenesis. 
However, interaction of VEGFR2 with VEGF is a major contributor to the mitogenic, 
chemotactic, angiogenic and increased permeability effects of VEGF70. Once VEGF binds to 
the extracellular domain of the receptor, after the dimerization and auto-phosphorylation 
of the intracellular receptor tyrosine kinases, a cascade of downstream proteins are 
activated54. 
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Due to the key role of VEGF in angiogenesis, the use of anti-VEGF drugs has been applied 
in many different fields of medicine, such as prevention of angiogenesis associated with 
tumors and induction of neovasculature in ischemic diseases3. 
 
Angiopoietins 
ANGPT family consists of four ligands: ANGPT1, 2, 3 and 4; and two tyrosine kinase 
receptors, TIE1 and TIE245. 
ANGs are paracrine growth factors that act as ligands for the TIE receptors, specifically on 
ECs, and are involved in the maintenance, growth and stabilization of the vessels71,72. The 
most important and well characterized ANGPTs that play a role in angiogenesis are ANGPT1 
and ANGPT2. Both ANGPT1 and ANGPT2 bind to TIE2 receptors, but only the binding of 
ANGPT1 results on signal transduction and regulation of blood vessel maturation55. Thus, 
the interaction between ANGPT1 and TIE2 receptor induces the remodeling and 
stabilization of blood vessels. ANGPT1 is expressed by mural and tumor cells, whereas 
ANGPT2 is released from angiogenic tip cells. In confluent endothelium, ANGPT1 induces 
the maintenance of quiescent endothelial cells through cell-cell junction. Also, ANGPT1 
stimulates mural coverage and basement membrane deposition, thereby promoting vessel 
tightness45. Studies have shown that knockout mice for ANGPT1 or TIE2 exhibit similar 
phenotypes, with prominent endocardial and myocardial defects. The primary vasculature 
of these mice develops normally, but the stabilization and remodeling of the vessels fails, 
leading to embryonic death65. On the other hand, overexpression of ANGPT1 in transgenic 
mice causes excessive hypervascularization, namely a greater number of blood vessels with 
large diameters73. Concerning ANGPT2, its role in angiogenesis is more complex. ANGPT2 
can act as a pro- or anti-angiogenic factor, dependent on co-stimulatory molecules, such as 
VEGF. At first, ANGPT2 was considered as a natural antagonist of ANGPT1, since it blocks 
ANGPT1-induced TIE2 autophosphorylation in ECs49. However, recent new studies suggest 
that in the presence of VEGF, ANGPT2 mediates an increase in the capillary diameter, 
induces migration and proliferation of ECs and stimulates sprouting of new blood vessels, 
while in its absence, ANGPT2 causes apoptosis of ECs and regression of blood vessels74. 
Despite the current difficulty to understand ANGPT2 activity, the selective inhibition of 
ANGPT2 may have clinical value. Several studies have shown ANGPT2 upregulation in some 
diseases that involve pathogenic angiogenesis including cancer, rheumatoid arthritis, 
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osteoarthritis and psoriasis75-77. Additionally, various agents that block either TIE2 or 
ANGPT2 are being evaluated in early-phase clinical trials45. Regarding TIE1 receptor, since 
no ligand has been identified, it may act as a negative regulator of TIE2, but its role remains 
undefined. 
 
Fibroblast Growth Factors 
FGFs are soluble growth factors that stimulate EC proliferation and migration, as well as 
production of collagenase and the plasminogen activator54. FGF family is known to contain 
at least 20 factors, numbered FGF1 to FGF20, and 4 different tyrosine kinase receptors 
(FGFR), numbered FGFR1 to FGFR4.  
The most studied forms are FGF1 (acid FGF) and FGF2 (basic FGF), which were among the 
first growth factors that were known to stimulate angiogenesis.  
They are both secreted by a wide range of cell types and bind to all four FGFR65. In addition, 
FGFs also bind, with high affinity, to heparin sulfate proteoglycans (HSPGs), which act as 
co-receptors. HSPGs are located on cell surface and within the ECM, modulating the effects 
of FGF both in vitro and in vivo78,79. Heparin induces oligomerization of FGF2, which might 
be important for receptor dimerization and activation. FGFR activation will then trigger an 
intracellular signal cascade leading to multiple biological responses, including ECs 
proliferation, migration, differentiation, protease production and angiogenesis55. 
FGFs stimulate angiogenesis directly by activating their receptors on ECs or indirectly by 
inducing the release of angiogenic factors from other cell types. For instance, in the heart, 
FGF-mediated signaling induces vessel growth by stimulating the release of hedgehog, 
ANGPT2 and VEGFB.  
FGF1 and FGF2 knockout mice develop and grow normally without any evident pathological 
phenotype, being their organogenesis and life span unaffected. However, mice lacking 
FGF2 show neuronal defects and exhibit delays in wound healing, suggesting that FGF2 
might regulate sprouting of new sites of tissue repair80,81. Additionally, tube formation 
stimulated by VEGF is totally abolished when neutralizing antibodies against FGF2 are 
added to the system, showing that in this particular setting, VEGF requires the presence of 
FGF2 to promote vessel assembly82. FGF signaling also contributes to the proliferation of 
tumor cells, either by an autocrine or paracrine mechanism82,83. 
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Moreover, disruption of the genes encoding FGFR1 or FGFR2 leads to embryonic death, 
which makes impossible to define the role of these receptors in the later stages of 
development and in angiogenesis84,85. 
 
Transforming Growth Factor β  
TGFβs are a family of homodimeric cytokines that include TGFβ1, 2, 3, 4 and 5. TGFβ binds 
to two different types of serine-threonine kinase receptors, known as type I (TGFβR1) and 
type II (TGFβR2). TGFβR1 and TGFβR2 are interdependent, meaning that TGFβR1 requires 
TGFβR2 to bind to TGFβ and TGFβR2 requires TGFβR1 for signaling. ECs also present 
another specific type III (co)receptor, endoglin, which is upregulated during angiogenesis. 
TGFβ helps to control many different cellular processes, including angiogenesis3. TGFβs are 
normally found in the ECM of many different cells types. In the microvasculature both EC 
and pericytes express TGFβRs and produce TGFβ, suggesting an auto- or paracrine loop for 
TGFβ86.  
An interesting property of TGFβ is that it is secreted as inactive precursors which need to 
become activated87. In vitro studies have shown their activation by heat, acidification and 
proteases88. Additionally, in vivo, activation of TGFβ by proteases could be a regulatory 
mechanism for TGFβ-mediated activity89. 
To date, both pro- and anti-angiogenic properties have been attributed to TGFβ, depending 
on the context. At low doses (<0.5 ng/ml), TGFβ helps to initiate the angiogenic switch by 
upregulating angiogenic factors and proteinases. However, at high doses, it inhibits EC 
growth, promotes basement membrane reformation and stimulates SMCs differentiation 
and recruitment71. 
Additionally, TGFβ reduces the degradation of the perivascular ECM by the induction of 
protease inhibitors and the reduction of proteases. On the other hand, TGFβ stimulates 
angiogenesis in vivo, leading to the formation of highly vascular granulation tissue two or 
three days after mice being subcutaneously injected90. 
Since TGFβ is not an EC mitogen, angiogenesis is indirectly stimulated through the 
recruitment of inflammatory cells, which in turn release pro-angiogenic cytokines65. TGFβ 
is highly chemotactic for monocytes, which under the influence of TGFβ are able to 
infiltrate a wound site and produce angiogenic factors91. However, a direct action is also 
possible through the binding of the two types of TGFβR1: ALK1 and ALK5 (activin receptor‐
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like kinase 1 and 5, respectively) and consequent activation of pro-angiogenic or 
maturation-specific genes92. 
Genetic studies in mice have shown that the loss of TGFβ leads to leaky vessels and lack of 
their structural integrity, leading to premature death93. TGFβ1 inactivation is lethal due to 
defects in the hematopoietic system and yolk sac vasculature94. 
TGFβ is also associated with pathological conditions, such as human hereditary 
hemorrhagic telangiectasia, which is characterized by vascular malformations. Genetic 
studies have shown that this disorder is caused by mutations in the genes that encode 
endoglin or ALK1 and ALK5, receptors of the TGFβ family. Studies in mice have shown that 
the loss of the TGFβRs results in arteriovenous malformations.  
 
Platelet-derived growth factor 
PDGF comprises four members: PDGF A, B, C and D, that exist at homo- or heterodimeric 
versions of PDGF. PDGF receptors (PDGFRs) are composed of two single α and β subunits 
and occur also as a homo- or heterodimers. PDGF was initially isolated from platelets, but 
fibroblasts, ECs, keratinocytes and various other cell types also express PDGF under certain 
conditions65. PDGF is an important signaling molecule with several different roles in 
angiogenesis. In ECs, PDGFRβ interacts with PDGFBB, and when the receptors are 
stimulated in vitro, the DNA synthesis increases and the angiogenic sprouting occurs3,54. 
Furthermore, PDGFB is mitogenic for SMCs and pericytes and induces the expression of 
VEGF and VEGFR2 in cardiac ECs95,96. Additionally, pericyte proliferation and migration in a 
growing blood vessel is enhanced by interaction with PDGF, although the initial recruitment 
of pericytes to growing vessels is PDGF independent97. The interaction of PDGF with its 
receptor on pericytes increases the expression of ANGPT1, which leads to a signaling 
cascade that facilitates the interaction between pericytes and ECs. This interaction is 
important to maintain the stability of newly formed capillary walls98. 
Knockout mice for the genes encoding PDGFB and PDGFRβ die prenatally from edema and 
hemorrhage caused by the absence of vascular mural cells. The large increase in the 
permeability of blood vessels found in mice deficient for PDGFB and PDGFRβ indicates that 
PDGF is essential for vessel stabilization99. Furthermore, PDGF appears to play an important 
role in pericyte recruitment in tumors. The inhibition of PGDFR reduces tumor growth by 
causing pericyte detachment, what leads to immature vessels prone to regression. 
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Paradoxically, others studies have shown that the overexpression of PDGFB in mice inhibits 
tumor growth by promoting pericyte recruitment and inducing EC growth arrest45. 
 
Hepatocyte Growth Factor 
HGF is mapped to an heavy α chain and a light β chain100. The inactive pre-pro-HGF 
becomes active after two cleavage processes in the ECM101. 
HGF is a multifunctional cytokine produced by cells of mesenchymal origin; however, HGF 
was purified for the first time from rat platelets and it was described as a potent mitogenic 
factor for mature rat hepatocytes in vitro102-105. 
Additionally, HGF binds exclusively to the product of the cMET proto-oncogene106-108. The 
MET receptor comprises a ligand-binding extracellular domain, a transmembrane region 
and a cytoplasmic domain with tyrosine kinase activity109. HGF/MET binding promotes its 
dimerization and autophosphorylation of tyrosine residues, and the downstream signaling 
pathways generate diverse cellular responses, such as proliferation, survival, motility, 
invasion and stimulation of angiogenesis110,111. In the angiogenic context, the ligand–
receptor interaction stimulates ECs to proliferate and migrate in vitro, induces blood vessel 
formation in vivo, and induces VEGF expression in human tumor cells112,113. Furthermore, 
the expression of HGF can be upregulated by several growth factors, cytokines and 
prostaglandins. 
Several studies involving disruption of HGF or MET showed that these knockouts are 
embryonically lethal, with impaired development in the liver and placenta, indicating that 
HGF signals are essential for organ development114,115. On the other hand, overexpression 
of the receptor has been implicated in different types of tumors116. Thus, the significant 
role of the HGF/MET pathway in diverse biological and physiological processes, such as 
organogenesis, morphogenesis, tissue regeneration and carcinogenesis is evident. 
Moreover, the one-to-one ligand-receptor relationship makes the HGF/MET axis an 
attractive target for drug development, either by activation or inhibition of this pathway100. 
 
Endostatin 
Endostatin is an anti-angiogenic 20-kDa internal fragment of the C-terminal of collagen 
XVIII117. Collagen XVIII is a component of basement membranes with structural properties 
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of both a collagen and a protheoglycan. Proteolytic cleavage within its C-terminal domain 
releases an endostatin fragment118. It was originally isolated from a 
hemangioendothelioma cell line for its ability to inhibit proliferation119. Endostatin 
interacts with many different cell surface proteins, including integrins and glypicans, and 
these interactions result in altered ECs adhesion and migration. In vitro studies have shown 
inhibition of ECs migration, proliferation and tube formation by endostatin3. Endostatin 
reduces ECs proliferation by arresting the EC cell cycle, through the downregulation of 
cyclin-D1 promotor transcriptional activity. Moreover, inhibition of angiogenesis via 
endostatin in vivo leads to a reduction of tumor growth, which is partially accomplished by 
the reduction of VEGF expression. Endostatin has the ability to block existing VEGF from 
interacting with its receptor VEGFR2117. Recent studies have also shown that endostatin 
disturbs the survival/death balance via activation of the pro-apoptotic pathway through 
the induction of caspase-9 activation3. 
Physiological function of collagen XVIII/endostatin has recently been uncovered through 
the identification of inactivating mutations in the human collagen XVIII/endostatin gene 
(COLI18A1) in patients with Knobloch syndrome, characterized by age-dependent 
vitreoretinal degeneration and occipital encephalocele. The essential role of collagen 
XVIII/endostatin in ocular development and in the maintenance of the visual function is 
further demonstrated in the ocular abnormities seen in mice lacking collagen 
XVIII/endostatin gene118. Furthermore, studies in mice lacking collagen XVIII and its 
proteolytically derived product endostatin show delayed regression of blood vessels in the 
vitreous along the surface of the retina vessels. These findings suggest that collagen 
XVIII/endostatin is critical for normal blood vessel formation in the eye120. 
 
Thrombospondin-1  
Thrombospondin1 (TSP1), a 142 kDa secreted glycoprotein, initially isolated from human 
platelets, was the first endogenous protein with anti-angiogenic properties to be 
identified121,122. TSP1, a member of a large family of matricellular proteins, plays an 
important role in genesis and remodelling of multiple tissues including cartilage and 
vasculature123. TSP1 is found in the extra- and pericellular matrix and regulate the 
extracellular milieu through a direct interaction with extracellular matrix proteins124. TSP1 
modulates expression of several genes involved in angiogenesis including TGFβ, VEGF and 
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its receptors, plasminogen activator, MMPs and CD36, inducing a quiescent state and a 
differentiated phenotype of vascular ECs125. TSP1 promotes the migration of SMCs but 
suppresses chemotaxis and motility of the ECs, stimulates matrix assembly through binding 
to other matrix proteins, such as fibronectin and collagen and regulates matrix digestion 
by MMPs and plasmin. Finally, TSP1 stimulates apoptosis of ECs but promotes the survival 
of SMCs123. The interaction of TSP1 with its receptor CD36 inhibits cell migration and 
induces apoptosis through down-regulation of Bcl2 and activation of caspases and the JNK-
MAP kinase pathway125. Animal studies shown that TSP1 inhibits EC migration and 
neovascularization in the rat cornea122. Also, the expression of TSP1 in various tumor cell 
lines prevents their aggressive growth and neovascularization when implanted in mice125. 
Moreover, in a context of retinal vasculature and neovascularization, studies with TSP1 
deficient mice showed an increased retinal vascular density and a reduced number of 
apoptotic nuclei during remodelling and maturation in TSP1 deficient mice when compared 
to the normal one125. 
 
Tumstatin 
Tumstatin is a 28 kDa cleaved fragment of type IV collagen, a basement membrane collagen 
found in the kidney, lung and other vascular basement membranes126. 
Tumstatin influences the sprouting and proliferation of ECs by interacting with their specific 
receptor and thus resulting in changes in the intracellular signaling and inducing anti-
angiogenic effects. Tumstatin inhibits angiogenesis by inducing apoptosis and inhibits EC 
proliferation through its binding to αvβ3 integrin124.  
Mice model studies have shown that administration of exogenous tumstatin inhibits tumor 
growth. However, tumstatin deficient mice had a much greater micro-vessel density near 
implanted murine tumors and a 300% increase in overall tumor growth3. Moreover, mice 
with a genetic deletion on tumstatin gene showed accelerated tumor growth associated 
with enhanced pathological angiogenesis, while angiogenesis associated with development 
and tissue repair were unaffected127. Animal studies determining the viability of tumstatin 
as an anti-angiogenic drug showed a reduction of over 90% in tumor size when compared 
with the controls3. 
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4.2. Pathological Angiogenesis 
In physiological conditions, the angiogenic balance is sustained by the activity of 
stimulators (pro-angiogenic factors) and inhibitors (anti-angiogenic factors). However, the 
loss of this balance becomes a critical factor in certain pathological conditions such as 
cancer, atherosclerosis, ischemia and diabetic retinopathy51. When more angiogenic 
growth factors than angiogenesis inhibitors are produced, the balance is tipped in favor of 
blood vessel growth, implicated in diseases like cancer51,128. Tumor vessels are 
architecturally different from normal ones, having an abnormal structure and function with 
apparently chaotic organization16. Vessels vary from abnormally wide, irregular and 
tortuous serpentine-like shape to thin channels with small or compressed lumens129. Every 
layer of the tumor vessel wall is abnormal: ECs form an imperfect lining, with wide junctions 
at some locations and stacked layers of ECs at others. ECs may contain many fenestrations, 
vesicle vacuolar organelles or both. The expression of adhesion molecules is also more 
heterogeneous than in normal tissue. Because of the abnormal organization and structure 
of tumor vessels, the blood flow is chaotic and the vessels are leaky. The resulting irregular 
perfusion impairs oxygen, nutrient and drug delivery6,50. 
On the other hand, when angiogenesis inhibitors are more produced than angiogenic 
growth factors, angiogenesis does not occur, resulting in ECs dysfunction, vessel 
malformation or regression and situations like ischemia or atherosclerosis may take 
place51,128.  
Both situations lead to an uncontrolled angiogenesis process. In this work, we will give 
especial attention to critical limb ischemia (CLI).  
 
4.2.1. Critical Limb Ischemia 
CLI is the most severe manifestation of peripheral arterial disease (PAD)130. PAD can be 
anatomically defined as an obstructive arterial disease or functionally as an arterial 
narrowing, causing a mismatch between oxygen supply and demand131. Thus, PAD is a 
medical condition that involves an obstruction in arteries that provide blood flow to the 
arms or legs, due to atherosclerosis132,133. CLI patients typically present chronic ischemic 
rest pain or ischemic skin lesions, either ulcers or gangrene and this condition is estimated 
to develop in 500 to 1000 individual per million per year134,135. Almost 50% of patients with 
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CLI have diabetes, which is a metabolic disorder of multifactorial etiology. Diabetes is 
characterized by chronic hyperglycemia and changes in the metabolism of carbohydrates, 
lipids and proteins, resulting in relative to absolute impairment in insulin secretion and/or 
reduction in its biological activity136. 
Patients with CLI have high mortality rates because the atherosclerotic disease is a systemic 
disease that does not localize to an isolated vessel segment. So, CLI is a chronic and complex 
process that affects the macrovascular and microvascular systems, as well as surrounding 
tissues137. This usually results from the presence of multilevel occlusive disease or occlusion 
of critical collaterals134. Additionally, CLI leads to alterations in structure and function of 
ECs. This endothelial dysfunction leads to micro thrombosis within the capillaries and 
exacerbates edema formation in their extremity. Furthermore, endothelial trauma results 
in increased free radical production, inappropriate platelet activation, and leukocyte 
adhesion, all of which lead to micro thrombi formation137. Capillary microscopy has shown 
initial tissue edema and pericapillary hemorrhage, followed by a reduction in the number 
of perfused capillaries, resulting in ischemic areas134. Once the diagnosis is confirmed, the 
goals for treating CLI are to relieve ischemic pain, heal ischemic ulcers and prevent limb 
loss. For that, it is crucial to control the risk factors such as hypertension, diabetes, 
dyslipidemia and smoking, thereby changing the life style and prolonging the survival of the 
patient137,138. Revascularization of ischemic areas may be the solution, but important issues 
must be considered, including the presence of comorbidity and arterial anatomy. It is 
mandatory to perform a risk-benefit analysis to determine the optimal therapy. A 
significant improvement in blood flow may diminish the symptoms of rest pain, but 
pulsatile flow to the foot is generally necessary for the treatment of ischemic ulcers or 
gangrene134,137. In patients not eligible for arterial reconstruction, pharmacotherapy using 
antiplatelet agents and vasodilators are the only option138. In these cases, prostanoids are 
the only vasoactive drugs with proven efficacy. Most studies have found that parenteral 
administration of either prostaglandin E1 or Iloprost reduces pain, ulcer size, and/or the 
need for amputation. However, amputation continues to be the recommended solution to 
the disabling symptoms, despite its associated morbidity and mortality rates. Only 50% of 
patients who are not candidates for revascularization will be alive without a major 
amputation one year after the onset of CLI. Furthermore, one-third of amputated patients 
die within one year, one-third achieve partial autonomy and only one-third obtain 
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complete autonomy134. Many clinical studies are being carried on with the goal of 
increasing or stimulating angiogenesis in patients with PAD or CLI137. 
 
5. Pro‐angiogenic therapy  
Pro-angiogenic therapy is introduced as a novel strategy for the treatment of vascular 
insufficiency139. There are three major disorders for which pro-angiogenesis therapy is 
clinically indicated: chronic wound, CLI and ischemic heart disease52. 
To successfully apply it, several conditions should be met: (1) newly formed blood vessels 
must be functional and supply the ischemic region with oxygenated blood; (2) the 
functional blood vessels must remain stable; and (3) the neovascularization in ischemic 
tissue should be tightly regulated to attain maximum efficiency. Thus, the aim of pro-
angiogenic therapy is to deliver highly effective angiogenic factors to the ischemic region, 
in order to increase the perfusion and function of an organ or tissue140. 
Several approaches have been considered to increase angiogenesis, including the 
evaluation of different angiogenic growth factors, of different treatment modalities and 
routes of administration (recombinant protein versus gene transfer) and of cellular 
techniques141. 
 
5.1. Local administration of pro-angiogenic growth factors 
Angiogenic growth factors have the ability to increase collateral vessels and augment tissue 
perfusion and oxygenation, limiting ischemic lesions in a variety of animal models of 
coronary or limb ischaemia142. The beneficial effects of growth factors in animal ischemic 
models led to a great expectation of its use for the treatment of CLI130. During the past 
decade, numerous clinical trials have been encouraged in a context of therapeutic 
angiogenesis and despite claims of success in an early state, clinical trials failed to 
conclusively show a clinical benefit143,144. VEFG family are among the most powerful growth 
factors that modulate vascular biology and have received much attention regarding their 
potential therapeutic effect in CLI. Others angiogenic growth factors, like members of the 
HGF, FGF, PDGF or TGFβ are also under study131,135,137,138,144-146. Unfortunately, the results 
have been quite disappointing and numerous reasons have been pointed out to explain 
this130,145. 
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Part of this failure can be attributed to the lack of efficiency of the delivery procedure. For 
example, naked DNA is poorly taken-up, but different types of DNA vector have been 
successfully used to increase the efficiency of gene transfer. However, even the best 
methods of gene transfer still encounter significant problems to achieve effective 
transfection rates that could result in clinically significant levels of protein production141. 
Another problem can be dose-response: low doses for longer-term administration have 
shown a better prognosis with fewer side effects, when compared with higher doses147. 
Moreover, blood vessel growth is a process too complex to be stimulated effectively by the 
administration of a single angiogenic cytokine. So, combining factors that are pro-
angiogenic, such as VEGF or FGF2, with pro-maturation factors, such as ANGPT1 or PDGFBB, 
that mediate pericytes recruitment, could prevent hyperpermeability and also stabilize the 
nascent vasculature140. Additionally, potential patient-related issues, such as the existence 
of co-morbidities, the use of other medications, circulation of angiogenic inhibitors and lack 
of target receptor expression in target tissues could contribute to the ineffective response 
to angiogenic stimulation148. Alternatively, the increase of cellular recruitment with the 
induction of local production by a cocktail of growth factors has been explored. Thus, in 
vitro studies have shown that the administration of MCP1, which increases the recruitment 
of monocytes to ischemic tissue, improves collateral flow in a rabbit model of hindlimb 
ischemia141.  
 
5.2 Cell-based therapeutic strategy 
An alternative strategy to achieve angiogenesis is through cell therapy, in which 
transplanted cells can be integrated into the neovasculature of the ischemic tissue to 
increase its density and perfusion145. Moreover, transplanted cells can secrete multiple 
endogenous growth factors, meaning that these cells will induce vascular growth in a 
paracrine manner148. The potential of EPCs therapy in hindlimb ischemia disease is 
currently being extensively studied149. In the process of neovascularization, EPCs can 
differentiate into ECs. Thus, EPCs from bone marrow or peripheral blood are expanded and 
concentrated ex vivo and then re-administrated into the ischemic region. This approach 
accelerates the process of neovascularization and could be an alternative to angiogenic 
factors140,142. The transplantation of EPCs significantly improved blood flow recovery and 
capillary density in several animal models of hindlimb ischemia33. Moreover, studies from 
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Asahara at al showed in vivo mobilization and incorporation of autologous EPCs application 
into sites of tissue ischemia and neovascularization in a rabbit model of hindlimb 
ischemia139,150. Also, EPCs transplantation induces blood flow recovery in the ischemic 
hindlimbs of both diabetic mice and rats, suggesting that EPC-mediated neovascularization 
can still occur under disease conditions33. These encouraging results from preclinical 
studies have rapidly led to several clinical trials, in which bone marrow-derived 
mononuclear cells (BM-MNCs) were administrated to patients with CLI151. Moreover, 
recent evidences indicate that BM-MNCs promote collateral vessel formation in patient 
with CLI144. A variety of cell types has been studied in cell therapy, including unselected 
BM-MNC or peripheral blood-derived mononuclear cells (PB-MNCs), which comprise a 
heterogeneous mix of blood cells and nonhematopoietic stromal cells (mesenchymal stem 
cells (MSCs) and EPCs) and selected EPCs isolated and purified from BM-MNCs or PB-
MNCs145,149. 
The first report on the use of BM-MNC in limb ischemia was the Therapeutic Angiogenesis 
Using Cell Transplantation (TACT) study, in which an intramuscular injection of autologous 
BM-MNC significantly improved the leg pain scale, ulcer size and pain-free walking 
distance, for at least 2 years. Also, a 3 years’ follow-up assessment showed significantly 
lower amputation rates144,149. In the last decade, several trials have been performed, 
indicating that the use of BM-MNCs or PB-MNCs in cell therapy is a feasible, relatively safe 
and potentially effective therapeutic strategy for CLI patients144,152.  
Also, a randomized controlled trial comparing BM-MNCs and bone marrow-derived 
mesenchymal stem cells (BM-MSCs) demonstrated a significant improvement in pain-free 
walking time in both groups after 6 months. Additionally, the patients administrated with 
BM-MSC had significantly greater collateral blood vessel scores than patients administrated 
with BM-MNCs153. Others cell types, such as adipose-derived regenerative cells, are 
currently being explored. Clinical studies using these cells are now required to determine 
whether these cells provide advantages for CLI treatment145. However, more clinical trials 
are needed to clarify the still open issues, including the selection of optimal cell type, 
isolation method, cell number, route of administration and paracrine stimulation 
mechanisms151. 
Particularly for CLI, it is disappointing that after extensive preclinical investigation and two 
decades of clinical trials of angiogenic or cell therapies, none has been approved.  
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5.3 The use of ionizing radiation as a novel approach 
Ionizing radiation is a type of energy released by atoms that travels in the form of 
electromagnetic waves (gamma or X-rays) or particles (electrons, neutrons, beta or alpha 
particles). Exposure to ionizing radiation comes mainly in the form of natural background 
radiation (from the earth, cosmic rays and the radioactivity naturally contained in the 
human body), but also from human-made sources, ranging from nuclear power generation 
to medical uses of radiation for diagnosis or treatment, prominently X-rays154.  
Radiotherapy is the treatment of diseases by using ionizing radiation. It is a widely applied 
and highly effective therapeutic modality for the majority of the solid malignant neoplasms, 
being applied alone or associated with chemotherapy and/or surgery155. It is classically 
delivered in fractionated schemes of typically of 1.8 to 2.0 Gy/daily dose, repeated until a 
potentially curative tumor specific dose has accumulated. 
In addition to treatment of malignant diseases, ionizing radiation therapy can also be used 
for successful treatment of benign or non-malignant conditions, namely a variety of 
inflammatory and painful joint disease (such as heel spurs, osteoarthritis, tendonitis)156. 
Several studies demonstrate that ionizing radiation can differently modulate the 
inflammatory process. For instance, low-dose ionizing radiation (LDIR) (<1 Gy) attenuates 
a pre-existing inflammation, while doses exceeding 1 Gy may act as an initiator of the 
inflammatory process157. It was also demonstrated that ionizing radiation can attenuate 
the pathology of autoimmune diseases in animal models. In a mice model of rheumatoid 
arthritis, a suppression of IL6 and IL7 production and up-regulation of regulatory T cells was 
demonstrated after repeated irradiation with 0.5 Gy. Studies using a mice model of 
multiple sclerosis showed suppression of pro-inflammatory cytokines, reduction of CD8+ T 
cells and induction of regulatory T cells after exposure to 0.5 Gy once per week during 4 
weeks156. 
In a scenario of hindlimb ischemia, Heissig at al revealed that doses of ionizing radiation 
between 2 and 10 Gy increases vasculogenesis in ischemic tissues158. This study shows that 
increased recruitment and activation of mast cells following ionizing radiation exposure 
alters the ischemic microenviroment and promotes vascular regeneration in an ischemic 
model. Therefore, these data showed a novel strategy of neovascularization and suggest 
another therapeutic use for ionizing radiation. Moreover, Thanik at al showed that a single 
dose of 5 Gy delivered to an ischemic full-thickness cutaneous flap improves vascularity in 
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two ways: (1) through upregulation of HIF1, leading to increased angiogenic and 
vasculogenic pathways and (2) by direct upregulation of MMP9, which mobilizes EPCs from 
bone marrow into the peripheral circulation159. This study suggests that ionizing radiation 
creates a stimulus for systemic response, leading to pro-angiogenic effects.  
Furthermore, in vitro studies from our research group demonstrated that LDIR, lower than 
0.8 Gy, enhances the migration of lung microvascular endothelial cells (HMVEC-L), without 
affecting their proliferation or survival. LDIR-induced endothelium activation occurs 
through the phosphorylating VEGFR2, which is a critical player in the angiogenic process. 
Using a zebrafish model, our group also showed that LDIR accelerates vessel formation by 
inducing angiogenic sprouting in embryos and increasing vessel density in adults. This 
knowledge was extended to different mouse models, where LDIR was found to promote 
angiogenesis and accelerate tumor growth and metastasis160. 
Overall, the results of these investigations may help to support the use of ionizing radiation, 
particularly LDIR, as an option for the treatment of ischemic diseases, namely in a setting 
of CLI156. 
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Aims 
Lower limb ischemia is a major health problem. Critical limb ischemia (CLI) is the term used 
for patients with chronic ischemic rest pain, ulcers, or gangrene attributed to inadequate 
blood flow or arterial occlusive disease. Because of the absence of effective treatment in 
the advanced stages of disease, amputation is undertaken, even though it is associated 
with morbidity and mortality. Therefore, the need for alternative treatment strategies in 
CLI patients is compelling and therapeutic angiogenesis is a promising tool to treat these 
patients. Recently, our lab found that LDIR, lower or equal to 0.8 Gy, activates VEGFR2, 
induces the production of VEGF in hypoxia and promotes angiogenesis in vivo.  
The overall goal of the work presented in this thesis is to study the effects of LDIR on 
neovascularization. For that, a mouse model of hindlimb ischemia was developed using 
C57BL/6 female mice. The major objectives of this thesis are:  
1) to identify the cellular and molecular mechanisms by which LDIR is able to 
promote therapeutic angiogenesis;  
2) to evaluate if LDIR promotes postnatal vascularization by augmenting the 
systemic circulation of EPCs and/or by homing and incorporation into sites of 
neovascularization in ischemic tissues;  
3) to demonstrate that LDIR promotes neovascularization in the setting of 
experimentally induced diabetic mice.  
 
The first two aims will be addressed in Chapter III. The last aim will be addressed in Chapter 
IV. Several cellular and molecular techniques, namely RT-PCR, immunohistochemistry, 
immunofluorescence, flow cytometry, ELISA, laser capture microdissection and 
diaphonization were used along these chapters. 
 
In this thesis, we propose an innovative and non-invasive strategy to induce therapeutic 
neovascularization in a mouse model of hindlimb ischemia. LDIR may therefore have a 
clinical significant impact in the treatment of PAD.  
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Abstract  
Aims We have previously shown that low-dose ionizing radiation (LDIR) induces 
angiogenesis but there is no evidence that it induces neovascularization in the setting of 
peripheral arterial disease. Here, we investigated the use of LDIR as an innovative and non-
invasive strategy to stimulate therapeutic neovascularization using a model of 
experimentally induced hindlimb ischemia (HLI). 
Methods and results After surgical induction of unilateral HLI, both hindlimbs of female 
C57BL/6 mice were sham-irradiated or irradiated with four daily fractions of 0.3 Gy, in 
consecutive days and allowed to recovered. We demonstrate that LDIR, significantly 
improved blood perfusion in the murine ischemic limb by stimulating neovascularization, 
as assessed by laser Doppler flow, capillary density and collateral vessel formation. LDIR 
significantly increased the circulating levels of VEGF, PlGF and G-CSF, as well as the number 
of circulating endothelial progenitor cells (EPCs) mediating their incorporation to ischemic 
muscles. These effects were dependent upon LDIR exposition on the ischemic niche (thigh 
and shank regions). In irradiated ischemic muscles, these effects were independent of the 
recruitment of monocytes and macrophages. Importantly, LDIR induced a durable and 
simultaneous up-regulation of a repertoire of pro-angiogenic factors and their receptors in 
endothelial cells (ECs), as evident in ECs isolated from the irradiated gastrocnemius muscles 
by laser capture microdissection. This specific mechanism was mediated via vascular 
endothelial growth factor (VEGF) receptor signaling, since VEGF receptor inhibition 
abrogated the LDIR-mediated gene up-regulation and impeded the increase in capillary 
density. Finally, the vasculature in an irradiated non-ischemic bed was not affected and 
after 52-wk of LDIR exposure no differences in the incidence of morbidity and mortality 
were seen.  
Conclusions These findings disclose an innovative, non-invasive strategy to induce 
therapeutic neovascularization in a mouse model of hindlimb ischemia, emerging as a novel 
approach in the treatment of critical limb ischemia patients.   
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Introduction 
Critical limb ischemia (CLI) is the end stage of peripheral arterial disease, and severe 
obstruction of blood flow to the affected extremity results in ischemic rest pain, ulcers or 
gangrene. Surgical revascularization remains the cornerstone of therapy for limb salvage 
but ~30% of CLI patients require amputation in the first year, procedure associated with 
high morbidity and mortality. Therapeutic angiogenesis became a promising treatment for 
limb preservation through the revascularization of ischemic tissues by local administration 
of pro-angiogenic growth factors 1-3. Several clinical trials showed that therapeutic 
angiogenesis could be extended to CLI patients 4. However, the initial enthusiasm was 
tempered by the less successful more recent, randomized and placebo-controlled studies 
with larger numbers of patients 4. Several factors could contribute to this: (i) formation of 
a functional vascular network requires the concurrent use of multiple angiogenic factors, 
and not a monotherapy-based approach; (ii) instability of currently used factors to achieve 
long-term benefits; and (iii) dysfunction of endothelial cells (ECs) that may not respond 5, 6. 
To solve this, cell-based therapeutic strategies were developed. Although clinical trials 
showed that autologous bone marrow-derived mononuclear cells, including endothelial 
progenitor cells (EPCs), increased collateral vessel formation and had clinical benefits 4, 
there are still major challenges that include determination of optimal cell phenotype, 
preparation protocols, dosing, route and frequency of administration. Moreover, 
endothelial dysfunction is associated with a scarce viable and functional EPC population 7.   
We previously showed that low-dose ionizing radiation (LDIR) (< 0.8 Gy) induces a pro-
angiogenic phenotype in ECs in vitro, and promote angiogenesis in vivo during regeneration 
8. Herein we aimed at testing an innovative non-invasive strategy, using LDIR to induce 
therapeutic neovascularization in CLI. Using a model of experimentally induced hindlimb 
ischemia (HLI), we show that LDIR improves limb reperfusion by enhancing collateral 
formation through EPC recruitment to sites of arteriogenesis. The effects of LDIR depend 
on exposure of the ischemic niche, but not on the local recruitment of myeloid cells. 
Moreover, LDIR induces capillary density in the gastrocnemius muscle by simultaneous 
activation of a repertoire of pro-angiogenic factors in a mechanism dependent of the 
vascular endothelial growth factor (VEGF) receptor signaling. No effects on resting 
vasculature were observed, disclosing the possibility of using LDIR as a non-invasive and 
effective therapeutic tool in lower limb vascular insufficiency. 
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Methods 
Expanded method descriptions are available in Supplementary material online.  
Study Approval 
All animal procedures were performed according to Directive 2010/63/EU. The procedures 
were approved by the institutional Animal Welfare Body, licensed by DGAV, the Portuguese 
competent authority for animal protection (license number 023861/2013). 
In vitro experiments 
Lung human microvascular endothelial cells (HMEC-L) were purchased from Lonza and 
cultured according to manufacturer’s instructions. Cells were used at passages 4-6. 
Affymetrix GeneChip HuGene 1.0 ST Arrays were used. 
In vivo experiments 
Twenty–two-week-old female C57BL/6 mice, purchased from Charles River Laboratories, 
Spain, were used in all experiments. Nine-week-old female C57Bl/6-Tg(CAG-EGFP)10sb/J 
mice were used as a donor in bone marrow transplantation model (Instituto Gulbenkian de 
Ciência). Unilateral HLI was induced by surgery. Ionizing radiation was delivered using a 
linear accelerator operating at a dose rate of 500 MU/min. In most experiments the dose 
of 0.3 Gy was administered for four consecutive days, starting 12 hours after ischemia 
induction. Blood flow was assessed by laser Doppler perfusion imaging. Capillary and 
collateral densities were assessed after immunohistochemistry and diaphonization, 
respectively. Capillaries were microdissected using a Zeiss PALM MicroBeam Laser 
Microdissection System. The immune cell infiltrate and EPCs were assessed by FACS. In 
plasma, cytokines were assessed by ELISA. RNA extraction, cDNA synthesis and qRT-PCR 
was performed using the primers described in the supplementary material online. After 52 
weeks post-HLI, body weights were recorded, urine, blood and different organs collected 
and analyzed.   
Statistics 
Experimental results are shown as the mean ± SEM. Data were analyzed with SPSS 20.0 
software for windows. Statistical test employed are detailed described in figure legends. 
For GeneChip data analysis, probe sets showing differential expression were determined 
using one-way Analysis of Variance (ANOVA).  
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Results  
LDIR increases perfusion recovery and capillary and collateral densities 
We used a previously established mouse model of HLI 9 to assess the effect of LDIR in the 
restoration of blood flow to ischemic muscle. After surgical induction of unilateral HLI, both 
hindlimbs were sham-irradiated or irradiated with four daily fractions of 0.3 Gy, in 
consecutive days (as illustrated in Figure 1A) and perfusion was measured overtime. As 
shown in Figure 1B and quantified in Figure 1C, a dramatic reduction in blood flow was 
observed in the ischemic limb immediately after surgery, in comparison to the contralateral 
limb, and as expected, a gradual improvement in perfusion was seen overtime. Strikingly, 
a significant improvement in blood flow recovery was seen in the LDIR group, at days 15 
and 45 post-HLI, comparing with sham-irradiated mice. This demonstrates a benefit of LDIR 
in the setting of HLI.  
Lower numbers of fractions (1 x 0.3 Gy; 2 x 0.3 Gy or 3 x 0.3 Gy) or lower dose per fraction 
(4 x 0.1 Gy) were also evaluated but failed to show an effect (Supplementary material 
online, Figure S1A and B). We also evaluated the effect of the same fraction over 7 days (7 
x 0.3 Gy), but no benefit was seen comparing within the 4-day (Supplementary material 
online, Figure S1C). 
Subsequently, we quantified capillary density and collateral vessel development in 
hindlimb muscles, since blood flow recovery depends on both angiogenesis and 
arteriogenesis. Consistently, HLI increases capillary density per se, assessed through 
quantification of CD31-positive capillaries on histological sections of gastrocnemius muscle. 
Importantly, this effect is further amplified after LDIR exposure and a significant increase 
in capillary density is observed in irradiated ischemic muscle versus the sham-irradiated 
ischemic ones at days 15 and 45 post-HLI (Figure 1D and 1E). Of note, while the capillary 
density did not significantly increase between days 15 and 45 in the sham-irradiated 
ischemic muscles, a significant increase is observed for the irradiated ones.  
The collateral vessel density (CVD) was evaluated, at days 15 and 90 post-HLI. Mice were 
diaphonized and an equivalent ROI, corresponding to 20% of the limb area, was selected 
for CVD quantification (Figure 1F). A greater increase in CVD was observed for the ischemic 
limbs of LDIR mice, versus the sham-irradiated ones (Figure 1G). Noteworthy, no difference 
in these parameters was seen in non-ischemic muscle, LDIR and sham-irradiated, showing 
that irradiation per se does not have an effect on resting vasculature.  
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Figure 1. LDIR increases perfusion recovery, capillary and collateral densities. 
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days and allowed to recover. (A) A 
schematic illustration of our experimental design. After unilateral HLI (represented by a thick 
brown line), the flow to the ischemic limb is dramatically decreased (in blue). Both hindlimbs are 
irradiated (in orange) or sham-irradiated. (B) Representative laser Doppler flow images pre-HLI, and 
at days 0 (d0) and 15 (d15) post-HLI induction. (C) Quantitative evaluation of blood flow expressed 
as a ratio of ISC to NISC limb demonstrated significantly enhanced limb blood perfusion in irradiated 
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mice vs sham-irradiated ones both at days 15 (d15) and 45 (d45) post-HLI. Between-group changes 
were assessed by two-way repeated measurements ANOVA followed by Bonferroni post-hoc test 
(n=12 mice per group). Means ± SEM are shown. (D) Representative sections from sham-irradiated 
and irradiated ischemic gastrocnemius muscles at day 45 post-HLI. Capillaries and myocytes were 
identified by CD31 immunohistochemistry and haematoxylin, respectively. Scale bar, 150µm. (E) 
Quantitative analysis revealed increased capillary density (capillaries/myocyte) in irradiated 
ischemic gastrocnemius muscles compared to sham-irradiated ischemic ones at days 15 and 45 
post-HLI. Mixed ANOVA followed by Bonferroni post-hoc test was conducted with a within-subject 
factor of ISC and between-subject factors of day and irradiation (n=6 mice per group). (F) Illustrative 
images of selected regions of interest (ROI) for sham-irradiated and irradiated mice. ISC and NISC 
limbs at day 90 post-HLI are shown. Scale bar, 300µm. (G) Data are represented as the percentage 
of collateral vessel density (CVD) increase of the ISC limb relatively to the NISC one. At days 15 and 
90 post-HLI, irradiated mice presented significantly higher CVD increase (%) versus sham-irradiated 
mice. Two-way ANOVA was conducted followed by Bonferroni post-hoc test with a between-
subject factors of day and irradiation (n=6 mice per group). (E, G) Individual data and means ± SEM 
(in red) are shown. *P < 0.05; *** P < 0.001; ns, non-significant. HLI, hindlimb ischemia; ISC, 
ischemic; NISC, non-ischemic; Pre-HLI, before hindlimb ischemia. 
 
LDIR modulates the expression of endothelial genes involved in an angiogenic response 
in vitro 
Previously, using human lung microvascular ECs (HMVEC-L) we showed that 0.3 Gy leads to 
rapid phosphorylation of the VEGF receptor 2 (VEGFR2) 8, a key signal transduction 
mediator.in the angiogenic process. Consequently, signaling pathways such as PI3K/AKT 
and ERK/MAPK are activated and gene expression modulated. To assess the effect of LDIR 
on the EC gene expression profile, HMVEC-L were exposed to a single dose of 0.3 Gy, RNA 
was extracted at 4 hours post-LDIR and a global gene expression analysis was performed; 
sham-irradiated HMVEC-L were used as control. Principal component analysis (PCA) 
revealed a separation of all HMVEC-L based on the irradiation status (Figure 2A). Two 
thousand three hundred and seventy-four genes were differentially expressed in LDIR vs 
control HMVEC-L, at a cutoff corresponding to a P value<0.03 (Figure 2B).  
Particular attention was paid to growth factors and receptors associated with angiogenesis, 
VEGF receptor 1 (VEGFR1) and VEGFR2, angiopoietin-2 (ANGPT2), transforming growth 
factor beta (TGF-β), platelet derived growth factor (PDGF) and fibroblast growth factor-2 
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(FGF-2), and their expression was validated by quantitative RT-PCR. Hepatocyte growth 
factor (HGF) and its receptor, MET, were also validated, as the use of HGF has been 
proposed in the setting of therapeutic angiogenesis, and clinical trials with HGF gene 
therapy are ongoing 4. HMVEC-L were irradiated with a single dose of 0.3 Gy and screened 
at 4, 8 and 12 hours post-LDIR. Gene expression increased at 4 hours post-LDIR, compared 
with sham-irradiated HMVEC-L, with exception of Tgfb2 whose increase was significant at 
8 hours post-LDIR. Expression levels of all genes returned to baseline at 12 hours post-LDIR 
(Figure 2C). We tried to modulate gene expression by increasing total dose (or number of 
fractions), using daily 0.3 Gy.fractions during 2, 3 and 4 consecutive days; and cells were 
screened at 4, 8 and 12 hours after the last irradiation. Regardless of total dose, gene 
expression pattern and magnitude were similar to that observed after the single irradiation 
dose experiment (Figure 2D-F).  
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Figure 2. LDIR modulates the expression of endothelial genes involved in an angiogenic 
response. 
Four RNA samples of irradiated (0.3 Gy) or sham-irradiated HMVEC-L were processed for 
hybridization to Affymetrix Human Gene 1.0 ST arrays. (A) Three-dimensional PCA plot. The red and 
blue points represent control (sham-irradiated) and irradiated samples, respectively, indicating a 
separation of samples based on the ionizing radiation stimulus. (B) Heatmap for the 2374 genes 
differentially expressed in LDIR vs control (one-way analysis of variance (ANOVA test) P < 0.03)). 
Columns and rows and represent biological replicates and individual genes, respectively. Red and 
green indicate genes up- or down-regulated compared to control cells (sham-irradiated), 
respectively. (C-F) HMVEC-L sham-irradiated or irradiated with 0.3 Gy (C) once; (D) twice, (E) three 
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or (F) four consecutive days.  (C-F) Data (means ± SEM) represent the fold change in gene expression 
relative to the internal calibrator (sham-irradiated) in triplicate measurements and are 
representative of four independent experiments. Data demonstrated a significant increase in the 
relative expression of Vegfr2, Vegfr1, Fgf2, Angpt2, Pdgfc, Hgf and Met, at 4 hours, and of Tgfb2 at 
8 hours post-irradiation, when compared to sham-irradiated cells (dashed line). Values assumed 
normal distribution, equal variance and independent two-tailed t-test was used; *P < 0.05; ** P < 
0.002. C, sham-irradiated; IR, irradiated.  
 
LDIR induces the expression of pro-angiogenic genes in ECs isolated from irradiated 
ischemic gastrocnemius muscles 
LDIR modulates the expression of angiogenic genes in a resting endothelial in vitro 
monoculture, not exposed to injury. Next, we evaluated the gene expression levels in ECs 
isolated from gastrocnemius muscle of mice subjected to HLI and exposed to LDIR in daily 
fractions of 0.3 Gy for 4 days or sham-irradiated. Forty-five days post-LDIR, mice were killed 
and gastrocnemius muscle sections stained for CD31 and visualized using a laser capture 
microdissection microscope (LCM). CD31-positive cells from ischemic and non-ischemic 
gastrocnemius muscles were dissected and isolated. First, we validated that these CD31-
positive cells consisted primarily of ECs and not myeloid cells nor perivascular cells. We 
assessed the gene expression of surface and transcription markers Pecam1 encoding CD31, 
Erg and Etv2 that are specific for ECs; Itgam encoding CD11b and Spi1 encoding PU-1 for 
myeloid cells and Des encoding Desmin, Pdgfrb and Acta2 encoding smooth muscle alpha-
actin for perivascular cells. The CD31+ cells isolated by LCM expressed high levels of 
endothelial-specific transcripts but negligible amounts (more than 10000 times less) of 
myeloid or perivascular-specific transcripts (Supplementary material online, Figure S2). 
Next, the same ECs were assessed by quantitative RT-PCR for the expression of Vegfr2, 
Vegfr1, Fgf2, Angpt2, Pdgfc, Tgfb2, Hgf and Met. Transcripts for all these genes were clearly 
up-regulated in ECs isolated from muscle of the ischemic limb, comparing with the 
contralateral limb, exclusively in mice exposed to LDIR (Figure 3A). Sham-irradiated mice 
show the opposite, down-regulating the expression of the angiogenic genes repertoire in 
endothelium from the ischemic limb, comparing with the contralateral limb. Then, we 
questioned whether the increase of the capillary density conferred by LDIR and observed 
in the ischemic gastrocnemius muscle could be correlated with the increase of the 
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expression levels of these pro-angiogenic genes. To address this, we used the adductor 
muscle that does not present an increase of the capillary density at day 45 post-HLI neither 
in response to ischemia per se, nor after LDIR exposure (Supplementary material online, 
Figure S3A). Thus, the adductor muscle provides a control subjected to HLI and irradiation 
without increase in the capillary density. We isolated the ECs from the adductor muscles 
and the levels of Vegfr2, Vegfr1, Fgf2, Angpt2, Pdgfc, Tgfb2, Hgf and Met mRNA were 
measured. We confirmed that the transcripts are down-regulated in the irradiated ischemic 
limb when compared with the contralateral one (Supplementary material online, Figure 
S3B). We have previously demonstrated that VEGFR tyrosine kinase inhibition impairs the 
LDIR-induced pro-angiogenic response 8. To assess the functional and clinical relevance of 
VEGF signaling induced by LDIR in the setting of HLI, VEGFR tyrosine kinase inhibition was 
achieved through oral gavage of PTK/ZK (100 mg/kg), after HLI and 2 hours before each 
LDIR exposure. VEGFR inhibition abrogated the LDIR-mediated gene up-regulation of pro-
angiogenic factors and receptors (Figure 3B). Moreover, the capillary density induced by 
LDIR, but not by HLI, was denied by treatment with PTK/ZK (Figure 3C). Conversely, the 
collateral density induced after LDIR exposure was not affected PTK/ZK (Figure 3D).  
Thus, 0.3 Gy administered during four consecutive days might act through VEGFR-signaling 
for angiogenesis, but not arteriogenesis in the ischemic gastrocnemius limb.  
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Figure 3. LDIR upregulates the expression of angiogenic genes in ECs isolated from 
irradiated ischemic gastrocnemius muscles.  
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days and allowed to recover. (A and B) 
At day 45 post-HLI, the expression of pro-angiogenic factors and their receptors was evaluated by 
qRT‐PCR exclusively on ECs. Gastrocnemius muscle sections were stained for CD31. Individual 
endothelial CD31+ cells were visualized, dissected and isolated using a laser capture 
microdissection microscope. (A) Each bar represents the relative gene expression in one animal. 
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White and gray bars represent sham-irradiated and irradiated mice, respectively. Values were 
normalized to 18S to obtain relative expression levels. Results expressed as log2 fold changes 
between ISC and NISC samples demonstrated relative abundance of the transcripts in irradiated 
mice; in contrast, a down-regulation is observed in sham-irradiated mice. (B-D) Two hours before 
each irradiation, ischemic mice were pretreated with PTK/ZK (100mg/Kg). (B) Light grey bars 
represent irradiated mice pretreated with PTK/ZK. A down-regulation in relative gene expression is 
found in irradiated mice treated with PTK/ZK. (C) Quantitative analysis, at day 45 post-HLI, revealed 
no difference in capillary density (capillaries/myocyte) between ISC irradiated vs ISC sham-
irradiated gastrocnemius muscles, both treated with PTK/ZK. As expected a significant increase is 
observed between ISC irradiated and PTK/ZK treated vs ISC irradiated and treated with the control 
vehicle. Mixed ANOVA followed by Bonferroni post-hoc test was conducted with a within-subject 
factor of ISC and between-subject factors of irradiation and PTK/ZK treatment. (D) Data are 
represented as the percentage of collateral vessel density (CVD) increase of the ISC limb relatively 
to the NISC one. At day 45 post-HLI, no difference was observed in CVD between irradiated mice 
treated with PTK/ZK vs irradiated mice treated with the control vehicle. Independent two-tailed t-
test was used. (C and D) Individual data and means ± SEM (in red) are shown from n=6 mice per 
group; *** P < 0.001; ns, non-significant. ISC, ischemic; NISC, non-ischemic. 
 
LDIR does not mobilize myeloid cells to the ischemic tissue 
Given that, in response to ischemia, the myeloid cells play an important role in the 
collateral formation 10 we questioned whether LDIR controlled the migration of myeloid 
cells in the ischemic tissue. Note that this process was already found for higher doses of 
ionizing radiation 11 (daily therapeutic doses ex: 2.0 Gy). Thus, after unilateral HLI, both 
hindlimbs were sham-irradiated or irradiated with four daily fractions of 0.3 Gy or 2.0 Gy 
as additional control. The myeloid infiltration was assessed day 4 post-HLI in ischemic and 
non-ischemic adductor muscles by flow cytometry (Figure 4A). As expected, the number of 
CD45+ cells increased significantly in response to HLI. Strikingly, exposure with 0.3 Gy or 
2.0 Gy inhibited the CD45+ cell accumulation (Figure 4B). Then we went on to assess which 
myeloid cells were modulated in the ischemic muscles. Monocyte and macrophage 
numbers increased significantly after HLI in sham-irradiated ischemic muscles. A similar 
response was observed in ischemic muscles upon 2.0 Gy exposure. In stark contrast, low 
0.3 Gy irradiation dose inhibited this monocyte and macrophage accumulation. This shows 
that different doses of ionizing radiation differently modulate myeloid cell infiltration in 
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response to ischemia (Figure 4C and D). Moreover, while neutrophil numbers increased 
substantially in response to HLI, both 0.3 Gy and 2 Gy irradiation dosages impaired this 
accumulation (Figure 4E). We also assessed whether at later time point myeloid cells could 
account for the increase in collateral density in response to LDIR. Fifteen days post-HLI the 
numbers of CD45+ cells, monocytes, macrophages and neutrophils were similar in the 
ischemic muscles in 0.3 Gy; 2 Gy or sham-irradiated groups (Supplementary material 
online, Figure S4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Profiles of leukocytes mobilized to ischemic muscles upon LDIR 
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy or 2.0 Gy in consecutive days. At day 4 post-HLI, analysis 
of CD45+ immune cells that infiltrate ischemic adductor muscles was assessed. (A) Representative 
analysis of hematopoietic CD45+ cells present in ischemic muscle as assessed by flow cytometry. 
Analysis of the accumulation of myeloid CD11b+ cells, and in particular macrophages 
(CD45+CD11b+F4/80+ cells), monocytes (CD45+CD11b+LY6C+F4/80int cells), and neutrophils 
(CD45+CD11b+Ly6Cint). The graphs show numbers of (B) total CD45+ cells; (C) monocytes; (D) 
macrophages and (E) neutrophils, isolated from ISC and NISC adductor muscles and represent the 
data derived from two independent experiments. Mixed ANOVA followed by Bonferroni post-hoc 
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test was conducted with a within-subject factor of ISC and between-subject factor of irradiation. 
Individual data and means ± SEM are shown (in red) from n=8 mice per group; *P < 0.05; ns, non-
significant. ISC, ischemic; NISC, non-ischemic. 
 
LDIR enhances collateral formation through EPC recruitment in a process that is 
dependent of the ischemic niche irradiation  
We next assessed the effect of LDIR on EPC mobilization from the bone marrow into the 
circulation. Total blood was collected at days 4, 5, 6 and 7 post-HLI and EPCs were identified 
by flow cytometry as mononuclear cells being VEGFR2+/ Sca-1+/ CD117+ cells. Consistent 
with the literature 12, significant increase of the percentage of EPCs occurred at day 6 in 
sham-irradiated mice in response to HLI (Figure 5A). Surprisingly, the percentage of 
circulating EPCs significantly increased already at day 4 post-HLI in irradiated mice, and to 
a level noticeably higher than in sham-irradiated mice at day 6 (Figure 5A). This suggests 
LDIR synergized with ischemia to increase EPCs in peripheral blood, a process that is not 
inhibited after PTK/ZK treatment (Supplementary material online, Figure S5A). 
In addition, we confirmed that LDIR increases the circulating EPCs percentage in a process 
dependent of ischemia induction (Supplementary material online, Figure S6). 
As EPC mobilization involves a complex network of migratory factors 2, 13, 14, we assessed 
whether LDIR modulates cytokine or chemokine concentrations synergistically with 
ischemia that could generate gradients that guided EPCs to areas of ischemia or/and locally 
induce arteriogenesis. We previously showed that in vitro and under hypoxia-mimicking 
conditions LDIR enhances VEGF expression in ECs 8. 
Using a similar approach, we found that in the presence of cobalt chloride (CoCl2), which 
mimics hypoxic conditions, ECs significantly increased Pgf mRNA (encoding placental 
growth factor (PlGF)) expression, in a way that synergized with exposure to 0.3 Gy 
(Supplementary material online, Figure S7). However, hypoxia and irradiation do not 
always synergize to regulate expression of migration factors. While Cxcl12 mRNA (encoding 
stroma-derived factor-1α (SDF-1α)) expression was increased by hypoxia but not by LDIR, 
conversely, Csf3 mRNA (encoding granulocyte-colony stimulating factor (G-CSF)) 
expression was induced by LDIR but not by hypoxia (Supplementary material online, Figure 
S7). These findings were confirmed in vivo by ELISA. VEGF, PlGF and G-CSF concentrations 
in the plasma were significantly increased in the plasma of irradiated mice at day 4 post-
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HLI when compared with sham-irradiated ones (Figure 5B). In contrast and consistent with 
our in vitro data, the levels of SDF-1α are not modulated by LDIR at least at day 4 post-HLI. 
Moreover, the levels of VEGF, PlGF and G-CSF were not changed in irradiated mice treated 
with PTK/ZK after HLI induction (Supplementary material online, Figure S5B).  
To confirm that this process is dependent of the effect of LDIR on the ischemic/hypoxic 
niche, we irradiated mice outside the ischemic niche. Since technically, it is not possible to 
irradiate only the non-ischemic hindlimb assuring that the contralateral ischemic one was 
not exposed to LDIR, we irradiated the upper (above hip) part of the mouse body 
(Supplementary material online, Figure S8A). Upper body LDIR exposition was not sufficient 
to increase the proportion of circulating EPC (Supplementary material online, Figure S8B). 
Consistently, the VEGF, PlGF, G-CSF and SDF-1α levels did not increase upon LDIR exposure 
(Supplementary material online, Figure S8C). Importantly, the increase by LDIR of collateral 
density is not achieved (Supplementary material online, Figure S8D). This strongly suggests 
that the exposure of the ischemic niche to LDIR is critical for the increase of cytokines, 
mobilization of EPCs and collateral formation. 
Next, we aimed to show that LDIR-induced circulating EPCs are functionally relevant for 
enhancement of their recruitment and incorporation into ischemic tissues. A bone marrow 
transplantation using C57Bl/6-Tg(CAG-EGFP)10sb/J donor was performed in C57Bl/6 mice 
and 8 weeks after, HLI was induced. Mice were sham-irradiated or irradiated with 0.3 Gy 
during four consecutive days and at day 15 post-HLI the adductor muscles were collected. 
Our results show that at day 15 post-HLI EPCs are recruited in the large vessels as identified 
by double-fluorescent labeling (green and red), in response to HLI (Figure 5C). To confirm 
the wide-field data, confocal images of the same ten-micron-thick section were acquired 
to show that green and red fluorescent signals belong to the same cells (Supplementary 
material online, Figure S9). Importantly, a quantitative evaluation of the histological 
sections revealed a significantly increased number of GFP+/CD31+ cells per area into 
irradiated ischemic thigh muscles when compared with the sham-irradiated ones (Figure 
5D).  
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Figure 5. Post-HLI induction, LDIR increases the number of circulating EPCs, the levels of 
VEGF, PlFG and G-CSF and mediate EPC recruitment in ischemia. 
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days. (A) Quantitative analysis of EPCs 
in peripheral blood demonstrated a significant increase of the percentage of EPCs in irradiated 
mice, at day 4 post-HLI and in sham-irradiated mice, at day 6 post-HLI when compared to the 
percentage before HLI induction (d0 pre-HLI). Interestingly, the increase conferred by LDIR at day 4 
in response to HLI is significantly higher to the one found at day 6 post-HLI in sham-irradiated mice. 
Two-way ANOVA was conducted followed by Bonferroni post-hoc test with a between-subject 
factors of day and irradiation; n=6 mice per group. Means ± SEM are shown. (B) The concentrations 
of VEGF, PlGF, G-CSF, and SDF-1α were measured in the plasma, at day 4 post-HLI. LDIR significantly 
increases the VEGF, PlGF and G-CSF concentrations after HLI induction vs sham-irradiation (n=10 
mice per group; values assumed normal distribution and equal or unequal (G-CSF) variance and 
independent two-tailed t-test was used). (C and D) Eight weeks after bone marrow transplantation, 
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HLI was performed in C57BL/6 mice. Mice were sham-irradiated or irradiated with 0.3 Gy during 
four consecutive days and at day 15 post-HLI the adductor muscles were collected. (C) At left, two 
representative images of incorporated EPCs identified by double-fluorescent labeling (green/red) 
in collateral vessels. Transplanted GFP:β-actin cells were identified by green fluorescence; 
vasculature by red fluorescence (CD31 staining) and nucleus by blue fluorescence (DAPI). Scale bar, 
25 µm. At right, single and merged channels after digital zoomed of the boxed areas are shown. (D) 
Quantitative analysis revealed a significant increase of EPCs incorporation (identified as 
GFP+/CD31+ cells) into irradiated ischemic muscles compared to sham-irradiated ischemic ones (n 
= 6 mice per group; values assumed normal distribution, unequal variance and independent two-
tailed t-test was used).  (B, D) Individual data and means ± SEM (in red) are shown; ** P < 0.01; *** 
P < 0.001; ns, non-significant.   ISC, ischemic; Pre-HLI, before hindlimb ischemia. 
 
LDIR exposure is not associated with increased morbidity or mortality  
To check for a possible effect of LDIR in the health status of the animals, a 52-week study 
was performed in a group of sham-irradiated and LDIR mice (n=140), throughout which 
mice were assessed for clinical signs of disease. There was no increased incidence of 
morbidity or mortality in the LDIR mice, compared with sham-irradiated, and there was no 
difference in body weight gain (at weeks 24, 36, 48 and 52 post-HLI). Fifty-two weeks post-
HLI mice were killed and no significant difference was observed in organ weight, serum 
biochemistry (n=24), urinalysis or hematological parameters (Table 1); and the histological 
analysis revealed no neoplastic lesions or major changes in the liver, lung, spleen, thymus 
or bone marrow of these mice (n=6) (Supplementary material online, Figure S10). 
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Table 1. Clinical, hematological, biochemical and histopathological data from sham-
irradiated and LDIR mice  
 
End Point                      0.0 Gy         4 x 0.3 Gy 
BW gain, % (n=140; mean ± SD) 14.2 ± 3.5 21.4 ± 5.3 
Mortality (n=140) 
Blood cell counts (n=24) 
2*/140 
WNRA 
1†/140 
WNR 
Clinical chemistry (n=24) WNR WNR 
Coagulation tests (n=24) WNR WNR 
Urinalysis (n=24) WNR WNR 
Bone Marrow cytology: abnormalities (n=6) 
Histopathological Analysis (liver; kidney; lung; bone marrow; 
spleen; thymus) (n=6) 
0/6 
0/6 
0/6 
0/6 
* found dead, from unknown cause. 
†sacrificed due to abscess formation after surgical procedure (HLI). 
A WNR, within normal range.   
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Discussion  
Therapeutic neovascularization aims to stimulate new blood vessel growth. Current 
strategies using proteins, genes or stem cells have demonstrated efficacy in animal models 
however, clinical translation remains challenging. We show that LDIR synergized with HLI 
and significantly enhance blood perfusion, capillary density in gastrocnemius muscle and 
collateral vessel development, tilting the angiogenic balance towards an even more pro-
angiogenic phenotype, and suggesting that LDIR may favor the functional recovery of 
ischemic tissues. In contrast, resting vasculature, not subjected to ischemia, are unaffected 
by LDIR since capillary density and CVD are similar in non-ischemic muscles exposed or not 
to LDIR. This is in agreement with our previous work, where inter-ray capillary density 
remained unchanged after LDIR of non-amputated zebrafish caudal fin 8. Our data also 
show that the maximal efficacy in perfusion recovery, capillary and collateral densities 
involves the administration of 1.2 Gy in four daily fractions of 0.3 Gy per fraction. A global 
gene expression analysis revealed that 2374 genes were modulated by LDIR and from 
those, 1344, many of which with a role in angiogenesis, were upregulated in LDIR versus 
control HMVEC-L. As soon as 4 hours after exposure to 0.3 Gy the expression of the majority 
of the pro-angiogenic molecules were increased, and returned to baseline12 hours post-
LDIR. This acute short-term effect of LDIR on ECs is independent from dose fractionation 
since cells exposed to 0.3 Gy administered 2, 3 or 4 consecutive days presented similar gene 
expression pattern and magnitude. The evaluation of expression of angiogenic genes in ECs 
isolated from gastrocnemius muscle of mice subjected to HLI revealed that LDIR modulates 
the expression of angiogenic genes in the endothelium and, thus, suggested a link for the 
long-term advantage in blood perfusion, capillary density and collaterals in HLI. LDIR 
induced a sustained and prolonged pro-angiogenic response in ECs, still evident 45 days 
after irradiation. Because this contrasts with the transient in vitro response, one may 
hypothesize either that endothelium itself could be differently modulated by LDIR in a 
hypoxic microenvironment created by ischemia; some cells (ex: adipocytes) could 
contribute to perpetuate the effect(s) of irradiation in ways that in vitro cultures cannot 
mimic. 
There is evidence that ionizing radiation can affect a variety of inflammatory processes and 
the composition of responding immune cells 15. However, this highly depends on the dose, 
for low doses (e.g. ≤ 1Gy) promote anti-inflammatory responses 16, while high doses (e.g. ≥ 
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2Gy) exert pro-inflammatory effects 17. Therapeutic applicability was further demonstrated 
on inflammatory disease as symptomatic improvement of rheumatoid arthritis was 
observed when mice were irradiated with 0.5 Gy in five fractions within 1 week 18. The 
hematopoietic infiltrate was monitored from inflamed and ischemic tissues to assess a 
potential role of immune cells upon LDIR. Ischemia per se induced about 20-foldsincrease 
in the immune CD45+ cell infiltrate recruited to the injured muscle at day 4 post-HLI. 
Exposure with 4x 0.3 Gy significantly inhibited the CD45+ cell accumulation with particular 
effects on monocytes, macrophages and neutrophils. In contrast, with 4x 2.0 Gy the total 
CD45+ accumulation in ischemic muscle was still reduced, and although numbers of 
monocytes and macrophages were restored, neutrophils were not. This is consistent with 
the fact that high irradiation doses have opposing effects on certain myeloid subsets, for 
they activate macrophages 19 while they are reported to induce rapid, but transient, 
neutropenia 20. Importantly, effect of irradiation was short-lasted. Fifteen days post-HLI the 
profiles of myeloid cells that infiltrated non-irradiated and irradiated ischemic muscles 
were similar. Altogether these data pointed for a mechanism of LDIR-induced 
arteriogenesis independent of local myeloid cell recruitment. 
In the setting of HLI we showed that LDIR boosts the induction of a sustained VEGFR-
mediated pro-angiogenic program in ECs from ischemic gastrocnemius muscle. These 
results corroborate our previous findings 8 and suggest a new mechanism: LDIR under HLI 
induces capillary density. Consistently, the capillary density induced by LDIR, but not by HLI, 
was abrogated by treatment with PTK/ZK. Conversely, the enhancement promoted in 
collateral density by LDIR was not affected by PTK/ZK, suggesting that this process is 
regulated by a mechanism independent of the VEGF receptor signaling.  
Consistent with our previous results showing that in hypoxic mimicking conditions, LDIR 
increases the expression of VEGF in ECs 8, here we found that the expression of Pgf and 
Csf3 is also increased in ECs. Importantly, these results were confirmed in vivo as VEGF, 
PlGF and G-CSF concentrations significantly increase in the plasma at day 4, upon LDIR 
exposure.  Of note, beside VEGF, the upregulation of other cytokines (such as PlGF and G-
CSF), might explain why circulating EPCs are insensitive to PTK/ZK inhibition. It is plausible 
that the effects of VEGF, PlGF and G-CSF are redundant on EPCs, and may explain why 
PTK/ZK does not affect the enhancement promoted in collateral density by LDIR. These 
cytokines were reported as being involved in the guidance of EPC to ischemic tissue 2, 13, 14. 
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In line with this, we observed EPC mobilization and recruitment to the ischemic tissue upon 
LDIR.  In the absence of ischemia, LDIR per se does not induce that effect and notably the 
irradiation of the ischemic tissue is critical for the mobilization of EPCs and collateral 
formation. Of note, in our transplantation model, all hematopoietic cells are GFP+ 
(including circulating and extravasated/tissue leucocytes, erythrocytes and platelets), but 
EPC, forming the inner lining of blood vessels, exhibit both green (GFP+) and red (CD31+). 
Thus, our results suggest that LDIR increases these growth factor concentrations 
synergistically with HLI and given the fact that this happens only if the ischemic tissue is 
irradiated, we hypothesize that a hypoxic niche is critical for this process. Although we 
cannot exclude that other cells could modulate the levels of these cytokines upon LDIR, our 
results strongly suggest the involvement of ECs.  
We propose a model of enhanced and sustained angiogenesis induction by in situ LDIR 
administration as a promising therapeutic approach for ischemic diseases (Figure 6).  
 
Figure 6. Proposed model of LDIR effect after HLI. 
After unilateral HLI (represented by a thick brown line), the flow to the ischemic limb is dramatically 
decreased (in blue) and vascular function is compromised as represented by a reduction in the dial. 
After LDIR exposure of both hindlimbs (in orange), we propose a synergistic effect occurs with the 
ischemic insult, tilting the dial towards an improvement of the vascular function by stimulating 
neovascularization.  Then, ECs in an hypoxic microenvironment secrete VEGF, PlGF and G-CSF 
leading to the recruitment of EPCs and consequently to collateral density increase. Simultaneously, 
the up-regulation of several pro-angiogenic target genes namely Vegfr (Vegfr-2 and -1), Fgf2, 
Angpt2, Pdgfc, Tgfb2, Hgf and Met in ECs induces capillary density. The vascular function of 
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nonischemic hindlimbs was not affected by LDIR exposure as represented by the dial in an 
equilibrium status before, during and after ischemia recovery. (© Diogo Guerra. 2016). 
 
LDIR applied as one daily irradiation of 0.3 Gy, administered for four consecutive days, 
synergistically act with the ischemic insult, exacerbating the local pro-angiogenic response. 
Our results suggest that this is achieved through (i) increased capillary density accompanied 
by an up-regulation of several pro-angiogenic target genes in ECs localized in gastrocnemius 
muscles, a process that is dependent of VEGF signaling and (ii) the mobilization and 
recruitment of EPCs by increasing the concentrations of VEGF, PlGF and G-CSF that may 
explain the collateral density increase in the ischemic limb leading to blood perfusion 
improvement.  
One important concern when addressing ionizing radiation is its toxic effect. According to 
the linear no-threshold (LNT) hypothesis, the dose-response is linear and no threshold 
exists where damage begins to show. Recent advances in radiobiology challenge the 
validity of the LNT suggesting that it overestimates radiation risks 21. We performed a 52-
week and LDIR had no significant impact in the morbidity and mortality of the mice, 
although the possibility of LDIR long-term toxicity cannot be ruled out. Importantly, the 
LDIR proposed herein is usually absorbed by healthy tissues during radiotherapy, in areas 
where no adverse effects were found during the follow-up of the patient for several years.  
The angiogenic potential of ionizing radiation has already been shown 22. We and others 
have shown that LDIR favors angiogenesis by promoting EC proliferation and migration, 
accelerating wound healing 8, 22. However, there is no consensus about the doses described 
as pro-angiogenic, as different radiation schemes are used. Herein, ionizing radiation was 
delivered through a linear accelerator producing photon beams, currently used in the 
clinical practice. The use of conventional radiotherapy dose (2-10 Gy, administered once, 
Caesium-137 source) has been shown to induce neovascularization in HLI through VEGF 
release from mast cells and MMP-9-mediated progenitor cell mobilization; however 
potential adverse effects were seen 11 and so, to the best of our knowledge, to date the 
use of those high doses has not been proposed for therapeutic neovascularization. 
Our data supports the use of LDIR in enhancing ischemia-induced neovascularization in 
vivo, which is achieved through the increase of cytokines, mobilization and recruitment of 
EPC to the ischemic tissue and simultaneous activation of a repertoire of pro-angiogenic 
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factors and resulting in enhanced recovery of blood flow. LDIR may therefore have a clinical 
significant impact in the treatment of peripheral arterial disease that represents a growing 
health problem worldwide, with high economic burden and limited therapeutic options. 
We currently have an ongoing exploratory clinical trial to determine the clinical and 
molecular effects in “non-option” CLI patients. The success of this clinical trial will lead to 
the development of new trials to propose a novel and effective therapeutic tool with 
worldwide impact to peripheral arterial disease.  
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Supplementary Material 
 
Supplementary Methods 
Cell Culture 
Lung human microvascular endothelial cells (HMEC-L) were purchased from Lonza and 
cultured according to manufacturer’s instructions. While different batches of primary cells 
were used over the course of the work, cells from the same batch were used in individual 
experiments (e.g. control vs. an experimental condition). Cells were used at passages 4 to 
6. 
 
Mice and Reagents 
Twenty–two-week-old C57BL/6 female mice, purchased from Charles River Laboratories, 
Spain, were used in all HLI experiments; and nine-week-old C57Bl/6-Tg(CAG-EGFP)10sb/J 
female mice (Instituto Gulbenkian de Ciência) were used as a donor mice in for bone 
marrow transplantation. Briefly, for the HLI procedure and in vivo imaging, animals were 
anesthetized with ketamine-medetomidine (75mg/Kg BW and 1 mg/Kg BW, respectively) 
and the anaesthesia was reverted with atipamezole (5mg/kg BW). Postoperatively, 
analgesia was administered (buprenorphine 100μl/15-30g BW q8-12 hours) and the 
animals were closely monitored. Mice were euthanized by cervical dislocation. 
PTK787/ZK222584 (PTK/ZK) (100 mg/Kg) was kindly provided by Novartis Pharma AG, 
Basel, Switzerland. PTK/ZK, polyethylene glycol-300 was used as vehicle (Sigma) and 
administered by oral gavage. The animals were randomly assigned to each experimental 
group. 
 
HLI Model 
A surgical procedure was performed to induce unilateral HLI in the mice. Briefly, an incision 
in the skin overlying the thigh of the right hindlimb of each mouse was made and the distal 
external iliac artery and the femoral artery and veins were ligated and excised. The vein 
was ligated both to increase the severity of the ischemia as well as to increase the technical 
reproducibility of the model, as isolation of the femoral artery alone often results in tearing 
of the vein resulting in hemorrhage.  
 
CHAPTER III 
81 
Irradiation 
The radiotherapy plan was devised on a dedicated 3D treatment planning system (XiO, 
Elekta) using an isocentric dose distribution of two opposite fields (0°, 180°) at 6 MV photon 
energy, normalized to a reference point. Ionizing radiation was delivered, at room 
temperature, using a linear accelerator that produces x-rays photon beam (Synergy S, 
Elekta) operating at a dose rate of 500 MU/min. 
Mice were transferred to an acrylic phantom in order to achieve the adequate thickness to 
improve homogeneity during the radiation therapy. A computed tomography scan 
(Somatom Sensation, Siemens) was performed and a volumetric acquisition was carried 
out; acquired images were reconstructed with axial slices width of 2 mm, and cross 
sectional data was transferred to the image processing system work station for contouring 
the planning target volume. 
A 0.6 cm3 PTW farmer ionizing chamber, connected to UNIDOS electrometer, was used to 
validate the IR doses calculated by the treatment planning system (TPS), according to the 
IAEA TRS-398 protocol. We obtained, in average, differences lower than 2% between the 
experimental and the XiO TPS dose values. The irradiation field included mice entire legs 
(pelvic girdle down to the feet) or the upper (above hip) part of the mouse body with a 
dose of 0.3 Gy administered for 4 consecutive days, starting 12 hours after ischemia 
induction. Control mice were sham-irradiated (0.0 Gy) following the same procedure for 
the irradiated experimental groups. The irradiation procedure was performed in a non-
blinded manner. During this protocol the mice were anesthetized. 
 
Laser Doppler perfusion imaging 
The laser Doppler perfusion imager (MoorLDI-V6.0, Moor Instruments Ltd, Axminster, UK) 
was used to assess limb perfusion. Hair was removed one day before laser Doppler analysis 
using an electrical shaver followed by depilatory cream. Blood flow was measured both in 
the ischemic and non-ischemic legs, before HLI induction (Pre-HLI), immediately post-HLI 
(Post-HLI), and at days 7, 15 and 45 post-HLI (d7 Post-HLI, d15 Post -HLI and d45 Post -HLI, 
respectively). According to the analysis performed immediately post-HLI, mice are 
randomized assuring an equal reduction of blood flow in the different experimental groups. 
Color-coded images of tissue perfusion were recorded and poor or no perfusion was 
displayed as darkblue, and the highest perfusion level was displayed as red. Mean flux 
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values were calculated using the Moor LDI V5.3 image processing software. To account for 
variables such as temperature and ambient light, blood perfusion is expressed as the ratio 
of ischemic to non-ischemic limb. The mice were placed on a 37°C heating pad to reduce 
heat loss during measurements.   
 
Immunohistochemistry and Capillary density analysis 
Mice were sacrificed at days 15 and 45 post-HLI. The gastrocnemius or adductor muscles 
of both legs were harvested, placed in transverse orientation on a small cork disc with the 
help of 10% tragacanth, snap frozen in liquid nitrogen cooled isopentane and stored at -
80ºC until sectioned. Seven-micrometer sections were labeled with CD31 monoclonal 
antibody (Pharmingen). After fixation in acetone, for 10 minutes, hydrogen peroxidase 
(0.3% diluted in methanol) was added, for 30 minutes, at room temperature, followed by 
2 washes in PBS, for 10 minutes. Blocking solution (5% rabbit serum in PBS) was applied, 
for 30 minutes, at room temperature, and then slides were incubated, for 1 hour, at room 
temperature, with rat monoclonal antibody against mouse CD31 at 1:500, diluted in PBS-
1% BSA. After 3 washes in PBS, for 30 minutes, a secondary biotinylated rabbit anti-rat IgG 
antibody was added at 1:200 in PBS-1% BSA plus 5% rabbit serum, for 30 minutes, at room 
temperature. Washes were performed as before and labeled avidin-conjugated peroxidase 
complex (Vectastain ABC kit; Vector Laboratories) was used for color development 
according to the manufacturer’s recommendations, for 30 minutes, at room temperature. 
After rinsing in PBS (3 times, for 5 minutes), DAB peroxidase substrate kit (Vector 
Laboratories) was added, for 5 minutes to localize the immune complexes. The sections 
were counterstained with Hematoxylin (Bio-Optica), for 10 seconds, and mounted with 
Entelan (Merck). Omission of the primary antibody was run in parallel as a negative control.  
Analysis of tissue samples was conducted using Leica DM2500 upright brightfield 
microscope (Leica Microsystems). Capillary densities, i.e. number of capillaries per number 
of muscle fibers, were measured in 2 different sections of 4 distinct anatomic areas of each 
specimen using the ImageJ software. 
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Contrast Agent Perfusion and Diaphonization 
Fifteen, forty-five and ninety days post-HLI induction, when mice were well stabilized from 
the ischemic injury, they were deeply anesthetized and the torso and limbs were shaved. 
A medial thoracotomy was performed to expose the heart and a needle (26 Gauge), 
attached to an automatic injector, was introduced in the left ventricle. An incision was 
performed in the right atrium to allow venous drainage. Mice were primarily perfused with 
heparinized serum (3000 IU/L) until the blood was completely removed from circulation. A 
vasodilatation mixture of adenosine (3.7 µmol/L) and papaverine (11.8 µmol/L) was 
subsequently administered, right before the contrast agent, for 2 minutes. The contrast 
used was a mixture of barium sulfate (50%) and gelatin (5%). This solution was kept warm 
until the injection time to avoid thickening. Contrast agent was perfused manually until the 
feet blanched. Right after the injection the mice were transferred to a cold chamber, so 
that the contrast agent became solidified. All the solutions were injected with a perfusion 
rate of 0.01 cm3/s. Then, the skin of each mouse was removed from the lower body and 
diaphonization was performed by using a modified version of Spalteholz technique. Briefly, 
the mice were fixated, decalcified, whitened, washed, dehydrated by freeze substitution 
and placed into a vacuum pump with Spalteholz solution (benzyl benzoate and methyl 
salicylate) until transparency was acquired. Diaphonization allows the visualization of 
effective lumen diameter, vessel angulation and emergence position.  
 
Collateral vessels quantification 
Mice were kept in Spalteholz solution during image acquisition, in order to achieve a 
homogenous density between the tissues and the media, with minimal absorption or 
reflection of light. Mice entire limbs were photographed in a magnifier with a light source. 
After acquisition, images were aligned and stitched together using Adobe Photoshop CS6 
and entire limb photographs were obtained. Collateral vessels were manually segmented 
by highlighting them using Adobe Photoshop CS6. We considered collateral vessels 
according to Longland’s definition, a defined stem, mid-zone and re-entrant. According to 
this definition, collateral vessels with a diameter between 20 and 300 µm were included in 
our quantification excluding femoral, saphenous and popliteal arteries and all venous 
structures. Since arteriogenesis occurs primarily around the occluded blood vessel 
segment, the region of interest (ROI) in every mouse was in the same anatomic region in 
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the adductor, surrounding and bellow the surgical occlusion. Collateral vessel density (CVD) 
was quantified in equivalent ROIs corresponding to 20% of the total limb area. The CVD 
was calculated as the ratio between the vascular area and the ROI areas. All density 
measurements were performed using ImageJ software. To exclude variations in the 
anatomy, perfusion or diaphonization procedures, the CVD value of the non-ischemic limb 
for each mouse was assumed to correspond to 100%. According to this assumption, the 
CVD percentage in the ischemic limb was calculated relatively to the non-ischemic one. The 
percentage of CVD increase was determined as the difference between the CVD percentage 
among the ischemic and non-ischemic limbs.  
 
Laser capture microdissection of capillaries 
Mice were sacrificed at day 45 post-HLI. Twelve-micrometer sections of the gastrocnemius 
or adductor muscles were labeled with CD31 monoclonal antibody (Pharmingen). The 
sections were stored at –80°C until microdissection. The immunohistochemistry protocol 
described above was modified to improve RNA preservation1 by using high salt buffer, 2 
mol/L NaCl in PBS (at 4ºC) in all incubation and washing steps. After 
immunohistochemistry, sections were dehydrated in ice cold 90% ethanol followed by 
100% ethanol and allowed to dry. Ten thousand capillaries were microdissected using a 
Zeiss PALM MicroBeam Laser Microdissection System (Carl Zeiss Microscopy, Germany) 
equipped with a pulsed solid-state 355 nm laser. Dissected capillaries were catapulted into 
a microfuge tube adhesive-cap. 
 
Isolation of immune cell infiltrate from muscle and FACS analysis 
Adductor muscles were excised after perfusing the mice with 30ml PBS. Muscles were cut 
in small pieces and digested for 30 minutes with collagenase I (1.5 mg/ml, Worthington) 
and DNase I (10 µg/ml, Sigma) diluted in DMEM. The digested product was filtered through 
a 70 µm mesh cell-strainers (Becton Dickinson) using a plunger to disrupt undigested tissue 
and washed with RPMI supplemented with serum. To isolate the leukocyte fraction, the 
cells were resuspended in 40% Percoll, overlayed on 80% Percoll and spun for 25 minutes 
at 2400 rpm without brake. The interphase containing leukocytes was recovered, washed 
and erythrocytes were osmotically lysed in red blood cell lysis buffer (BioLegend). For cell 
surface staining, single-cell suspensions were incubated, in presence 5% normal mouse 
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serum, for 30 minutes with saturating concentrations of combination of the following 
monoclonal antibodies that were purchased from BD Biosciences, eBiosciences or 
Biolegend: FITC anti-CD3 (145-2C11), PE anti-CD69 (H1-2F3), PerCP-Cy5.5 anti-Ly6G (1A8), 
PE-Cy7 anti-F4/80 (BM8), APC anti-CD11b (M1/70), APC-Cy7 anti-CD19 (1D3), brilliant 
violet 510 anti-CD45 (30-F11), brilliant violet 605 anti-Ly6C (HK1.4), brilliant violet 711 anti-
4 (N418). Zombie violet dye (BioLegend) was then added to the final suspension for 10 
minutes, at 4oC in order to stain and exclude dead cells. Cells were then immediately 
analyzed by flow cytometry on LSR Fortessa (BD Biosciences). All graphical output was 
performed using FlowJo 10 (Tree Star, Costa Mesa, CA). 
 
Endothelial progenitor cells and FACS analysis 
Terminal peripheral blood collection was performed transcardially, to an EDTA-coated 
tube, and erythrocytes were osmotically lysed in red blood cell lysis buffer (BioLegend). 
Then, cells were incubated, in presence of PBS - 5% BSA, for 30 minutes with saturating 
concentrations of combination of the following monoclonal antibodies purchased from 
Invitrogen, eBioscience or BD Pharmingen: TOPRO 3, biotin anti-Ter119, PE-Cy7 anti-
CD117, FITC anti-Sca-1, PE anti-VERGFR2. For Ter119, a secondary eFluor 450 streptavidin 
was used. Cells were then immediately washed with PBS and analyzed by flow cytometry 
on LSR Fortessa (BD Bioscience). All graphical output was performed using FlowJo 10 (Tree 
Star, Costa Mesa, CA). 
Endothelial progenitor cells (EPCs) were quantified within the monocytic cell population, 
by a dual expression of VEGFR2 and Sca-1 in the CD117 gate. 
 
Circulating Cytokine Quantification 
Peripheral blood was obtained by cardiac puncture at day 4 post-HLI induction. Blood was 
centrifuged 30 minutes and plasma separated from the cellular fraction and stored at -
20ºC. In plasma, vascular endothelial growth factor (VEGF), granulocyte-colony stimulating 
factor (G-CSF), placenta growth factor (PlGF) and stroma-derived factor-1α (SDF-1α) were 
measured via ELISA (R&D Systems) according to manufacturer’s instructions. 
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Bone Marrow Transplantation Model and Immunofluorescence 
Bone marrow cells were obtained by flushing the tibia and femur of eight-week-old 
C57BL/6 female mice C57Bl/6-Tg(CAG-EGFP)10sb/J (donor mice). Mononuclear cells were 
isolated by density centrifugation and filtered in a 70 µm cell strainer (BD). 
The transplantation was done in ten-week-old C57BL/6 female mice (recipient mice), 
lethally irradiated with 900 rads (Gammacell 3000Elan). After irradiation, the recipient 
mice received unfractionated bone marrow cells (5x106) from the donor mice by tail vein 
injection. Eight weeks after, HLI was induced and mice were sacrificed at day 15 post-HLI. 
The adductor muscles of both hindlimbs were harvested, placed in transverse orientation 
on a small cork disc with the help of 10% tragacanth, snap frozen in liquid nitrogen cooled 
isopentane and stored at -80ºC until sectioned. Ten-micrometer sections were labeled with 
CD31 monoclonal antibody (Pharmingen) and purified rabbit anti-GFP (Torrey Pines 
BioLabs Inc). After fixation in acetone, for 10 minutes, 0.5%Triton x-100 was added, for 10 
minutes, at room temperature followed by 2 washes in PBS, for 10 minutes. Blocking 
solution (10% goat (DakoCytomation) plus 10% donkey (Sigma-Aldrich) serum in PBS-1% 
BSA) was applied, for 30 minutes, at room temperature, and the slides were then incubated 
for 1 hour, at room temperature, with a rat monoclonal antibody against mouse CD31 and 
rabbit anti-GFP in PBS-1% BSA. After 3 washes in PBS-0.1%Tween, for 15 minutes, 
secondary antibodies goat anti-rat Alexa fluor 594 (Invitrogen) and goat anti-donkey Alexa 
fluor 488 (Invitrogen) were added in PBS-1% BSA, for 1hour, at room temperature. Washes 
were performed as before. Sections were incubated with Dapi (Sigma-Aldrich), for 10 
minutes, washed in PBS, for 5 minutes, mounted with vectashield mounting medium 
(Vector Laboratories) and seal with nail polish. Omission of the primary antibodies was run 
in parallel as a negative control. Analysis of tissue samples was conducted using a 
Motorized Widefield Fluorescence Microscope (Zeiss Axiovert 200M) with a 20x/0.8 
objective or confocal microscope (Zeiss LSM 880) with a 63x/1.4 oil immersion objective, 
with the pinhole set to 1 Airy unit (optical slice thickness = 0.7 micron). The number of EPC, 
defined as GFP+ CD31+, was measured on an area of 4.30 mm2 into 5 different sections of 
the adductor muscle for each specimen. All measurements were performed using ImageJ 
software. 
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RNA extraction, cDNA synthesis and pre-amplification 
Total RNA from the microdissected capillaries or HMEC-L was isolated using an RNeasy 
Micro or Mini Kit (QIAGEN) including DNase treatment, respectively. For synthesis and 
preamplification of cDNA RT2 PreAMP cDNA Synthesis kit (QIAGEN) was used with two 
rounds of pre-amplification using the following murine primers:  
 
Vegfr1_F (5’-TTGAGGAGCTTTCACCGAACTCCA-3’)  
Vegfr1_R (5’-TATCTTCATGGAGGCCTTGGGCTT-3’)  
Vegfr2_F  (5’-AGGCCCATTGAGTCCAACTACACA-3’)  
Vegfr2_R  (5’-AGACCATGTGGCTCTGTTTCTCCA-3’)  
Fgf2_F  (5’-ACTCCAGTTGGTATGTGGCACTGA-3’) 
Fgf2_R  (5’-AACAGTATGGCCTTCTGTCCAGGT-3’)  
Tgfb2_F  (5’-GCTTTGGATGCGGCCTATTGCTTT-3’)  
Tgfb2_R  (5’-CTCCAGCACAGAAGTTGGCATTGT-3’)  
Ang2_F  (5’-ATCCAACACCGAGAAGATGGCAGT-3’) 
Ang2_R (5’-AACTCATTGCCCAGCCAGTACTCT-3’)  
Pdgf-c_F  (5’-ATGCCACAAGTCACAGAAACCACG-3’) 
Pdgf-c_R  (5’-AAGGCAGTCACAGCATTGTTGAGC-3’)  
Hgf_F  (5’-GCATTCAAGGCCAAGGAGAAGGTT-3’)  
Hgf_R   (5’-TCATGCTTGTGAGGGTACTGCGAA-3’)   
C-met_F  (5’-ACGTTGAAATGCACAGTTGGTCCC-3’) 
C-met_R (5’-TTGCGTCGTCTCTCGACTGTTTGA-3’)  
Pecam_F (5’-CCCATCACTTACCACCTTTATG-3’) 
Pecam_R (5’-TGTCTCGGTGGGCTTAT-3’) 
Etv2_F  (5’-CACCGATCACACCAATGAA-3’) 
Etv2_R  (5’-GTACGTCTTCGTGAGGTAAAG-3’) 
Erg1_F  (5’-CCAAACTGGAGGAGATGATG-3’) 
Erg 1_R (5’-GTGCTGCTGCTGCTATTA-3’) 
Spi1_F  (5’-GCGCTGGCACCTTTTTGTAT-3’) 
Spi1_R  (5’-CAATAATTTTACTTGTCTTTAGTGGTTA-3’) 
Itgam_F (5’-TCTACTACCCATCTGGCTTATC-3’) 
Itgam_R (5’-TGGACTCAGCAGGCTTTA-3’) 
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Des_F  (5’-GCCACCTACCGGAAGCTACT-3’) 
Des_R  (5’-GCAGAGAAGGTCTGGATAGGAA-3’) 
Pdgfr_F (5’-GTGGTGAACTTCCAATGGACG-3’) 
Pdgfr_R (5’-GTCTGTCACTGGCTCCACCAG-3’) 
Acta2_F (5’-CCAGCACCATGAAGATCAAG-3’) 
Acta2_R (5’-TGGAAGGTAGACAGCGAAGC -3’) 
18s_F  (5’-GCCCTATCAACTTTCGATGGTAGT-3’) 
18s_R  (5’-CCGGAATCGAACCCTGATT-3’) 
 
Real-time PCR was performed according to the manufacturer’s protocol using Power 
SYBR Green (Applied Biosystems) and an Applied Biosystems 7500 Fast Real-Time PCR for 
the same targets described above. Human primer sequences are as follows:  
 
Vegfr1_F (5’-CCCTCGCCGGAAGTTGTAT-3’)  
Vegfr1_R (5’-GTCAAATAGCGAGCAGATTTCTCA-3’)  
Vegfr2_F  (5’-ATTCCTCCCCCGCATCA-3’)  
Vegfr2_R  (5’-GCTCGTTGGCGCACTCTT-3’)  
Fgf2_F  (5’-GCAGTGGCTCATGCCTATATT-3’) 
Fgf2_R  (5’-GGTTTCACCAGGTTGGTCTT-3’)  
Tgfb2_F  (5’-GCTTTGGATGCGGCCTATTGCTTT-3’)  
Tgfb2_R  (5’-CTCCAGCACAGAAGTTGGCATTGT-3’)  
Ang2_F  (5’-AGGACACACCACGAATGGCATCTA-3’) 
Ang2_R (5’-TGAATAATTGTCCACCCGCCTCCT-3’)  
Pdgf-c_F  (5’-AGGTCTTCAATCGTGGAAAGAA-3’) 
Pdgf-c_R  (5’-CAGAACCCAGCTAGTGGAATAC-3’)  
Hgf_F   (5’-GGTAAAGGACGCAGCTACAA-3’)  
Hgf_R   (5’-AGCTGTGTTCGTGTGGTATC-3’)   
C-met_F  (5’-CTGGTTCCTGGGCACCGAAAGATAAA-3’) 
C-met_R (5’-CCATTGCTCCTCTGCACCAAGGTAAA-3’)  
Pgf_F  (5’-CATGCAGCTCCTAAAGATCC-3’) 
Pgf_R  (5’-CTTTCCGGCTTCATCTTCTC-3’) 
Cxcl12_F (5’-TCTCAACACTCCAAACTGTG-3’) 
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Cxcl12_R (5’-TCTCCAGGTACTCCTGAATC-3’) 
Csf3_ F (5’-GATGGAAGAACTGGGAATGG-3’) 
Csf3_R  (5’-AAGCTCTGCAGATGGGA-3’) 
18s_F  (5’-GCCCTATCAACTTTCGATGGTAGT-3’) 
18s_R  (5’-CCGGAATCGAACCCTGATT-3’) 
 
The housekeeping gene used to normalize was 18S. The RT-PCR program consisted of an 
initial denaturation step, at 95ºC, for 10 minutes followed by 50 cycles, at 95ºC, for 15 
seconds and, at 60ºC, for 1 minute. The relative quantification was performed according to 
the comparative method (2-Ct; Applied Biosystems User Bulletin no. 2P/N 4303859), with 
non-ischemic muscle as internal calibrator. The formula used is 2-Ct =2-[Ct (sample) - Ct 
(calibrator)], where Ct (sample) =Ct (sample) –Ct (reference gene). For the internal calibrator, 
Ct=0 and 20=1. For the remaining samples, the value of 2-Ct indicates the fold change 
in gene expression relative to the calibrator. Ct value for each sample is the average of 
triplicates. 
 
Clinical Pathology and Histological Analyses 
Fifty-two weeks post-HLI, body weight was recorded and mice were sacrificed with 
anesthetic overdose. Blood was collected by cardiac puncture and assessed for complete 
blood cell count, serum biochemistry (urea, creatinine, alanine aminotransferase, 
aspartate amino transferase, alkaline phosphatase, phosphorus and albumin) and 
coagulation tests (prothrombin time, activated partial thromboplastin time, thrombin time 
and fibrinogen assay). Urine was collected by urinary bladder puncture for urinalyses.  
Necropsy was performed and several organs and tissues were collected for routine 
cytological and histopathology analysis: bone marrow smears were performed from 
flushed bone marrow (femur), and lung, liver, kidney, thymus, spleen, lymph nodes and 
long bone (femur) were collected, formalin-fixed and paraffin embedded. Hematoxylin and 
eosin-stained 3 μm sections were analyzed by a pathologist blinded to experimental 
groups.  
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RNA Isolation, Target Synthesis and Hybridization to Affymetrix GeneChips 
Total RNA was extracted using the RNeasy Micro Kit (QIAGEN) including DNase treatment. 
Concentration and purity was determined by spectrophotometry and integrity was 
confirmed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay (Agilent 
Technologies, Palo Alto, CA).  
RNA was processed for use on Affymetrix (Santa Clara, CA, USA) GeneChip HuGene 1.0 ST 
Arrays, according to the manufacturer’s Whole Transcript Sense Target Labeling Assay. 
Briefly, 100 ng of total RNA containing spiked in Poly-A RNA controls (GeneChip Expression 
GeneChip Eukaryotic Poly-A RNA Control Kit; Affymetrix) was used in a reverse 
transcription reaction (GeneChip WT cDNA Synthesis Kit; Affymetrix) to generate first-
strand cDNA. After second-strand synthesis, double-stranded cDNA was used in an in vitro 
transcription (IVT) reaction to generate cRNA (GeneChip WT cDNA Amplification Kit; 
Affymetrix). 15 µg of this cRNA was used for a second cycle of first-strand cDNA synthesis 
(GeneChip WT cDNA Synthesis Kit; Affymetrix). 5.5 µg of single stranded cDNA was 
fragmented and end-labeled (GeneChip WT Terminal Labeling Kit; Affymetrix). Size 
distribution of the fragmented and end-labeled cDNA, respectively, was assessed using an 
Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay. 5 µg of end-labeled, fragmented 
cDNA was used in a 100 µl hybridization cocktail containing added hybridization controls. 
80 µl of mixture was hybridized on arrays for 17 hours, at 45ºC. Standard post hybridization 
wash and double-stain protocols (FS450_0007; GeneChip HWS kit, Affymetrix) were used 
on an Affymetrix GeneChip Fluidics Station 450. Arrays were scanned on an Affymetrix 
GeneChip scanner 3000 7G.  
 
GeneChip Data Analysis 
Scanned arrays were analyzed first with Affymetrix Expression Console software for quality 
control. Subsequent analysis was carried out using Partek Genomics Suite 6.4. Here the 8 
arrays were normalized and modeled using Robust Multichip Averaging RMA. Probe sets 
showing differential expression were determined using 1-way Analysis of Variance 
(ANOVA) with a p-value cut-off of 0.03. Expression values of these 2374 well-annotated 
genes were imported into Chipster 3.7.2. Arrays and genes were clustered using Pearson 
correlation as a distance measure and average linkage for constructing a dendrogram, 
subsequently visualized as a heatmap. Microarray data are available in the Gene Expression 
CHAPTER III 
91 
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) under accession number 
GSE73341. Reviewer access: 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=afybsswgdfmlrsp&acc=GSE7334
1). 
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Supplementary figures 
 
Supplementary Figure 1: Perfusion recovery after exposure to different doses of IR.  
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with (A) 0.3 Gy, once, twice or three consecutive days (B) 0.1 Gy for four consecutive 
days (C) 0.3 Gy for seven days. Quantitative evaluation of blood flow expressed as a ratio of ISC to 
NISC limb was assessed before (Pre-HLI) and at days 0, 7, 15 and 45 post-HLI induction. At days 15 
and 45 post-HLI, blood perfusion is significantly induced in mice exposed to 0.3 Gy during seven 
days. Between-group changes were assessed by two-away repeated measurements ANOVA 
followed by Bonferroni post-hoc test (n=6 mice per group). Means ± SEM are shown. *** P < 0.001. 
ISC, ischemic; NISC, non-ischemic; Pre-HLI, before hindlimb ischemia. 
0.0 Gy 
4x 0.1 Gy 
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Supplementary Figure 2: The CD31+ cells isolated from laser capture microdissection 
microscope express consisted primarily of ECs and no myeloid nor perivascular cells 
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days and allowed to recover. At day 45 
post-HLI, gastrocnemius muscles were harvested sectioned, and stained for CD31. Individual 
endothelial CD31+ cells were and visualized, dissected and isolated using a laser capture 
microdissection microscope. To ensure that only ECs were isolated, the expression of markers 
specific for endothelium, myeloid or perivascular cells was assessed at the gene levels by qRT‐PCR 
exclusively on ECs. The cell markers Pecam1 encoding CD31, Erg and Etv2 that are specific for ECs; 
Itgam encoding CD11b and Spi1 encoding PU-1 for myeloid cells; and Des encoding Desmin, Pdgfrb 
and Acta2 encoding smooth muscle alpha-actin for perivascular cells were assessed. The relative 
mRNA levels were determined by real time qRT-PCR relative to the level of 18S RNA expression. 
Each symbol represents data obtained from isolated individual ECs pooled from one mouse and 
means ± SEM (in red) are shown from n=6 mice per group; ns, non-significant. ISC, ischemic; NISC, 
non-ischemic.  
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Supplementary Figure 3: Capillary density is not increased in the adductor muscles 
neither in response to ischemia nor upon LDIR and ECs do not present an up-regulation 
of pro-angiogenic genes.  
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days and allowed to recover. (A) At day 
45 post-HLI, quantitative analysis does not show an increase in capillary density 
(capillaries/myocyte) in irradiated ischemic adductor muscles compared to sham-irradiated 
ischemic ones. Furthermore, capillary density is not increased in adductor muscles in response to 
ischemia per se. Mixed ANOVA followed by Bonferroni post-hoc test was conducted with a within-
subject factor of ISC and between-subject factor of irradiation. Individual data and means ± SEM (in 
red) are shown from n=6 mice per group; ns, non-significant. (B) At day 45 post-HLI, the expression 
of pro-angiogenic factors and their receptors was evaluated by qRT‐PCR exclusively on ECs isolated 
from the adductor muscles. Each bar represents the relative gene expression in one animal. White 
and gray bars represent sham-irradiated and irradiated mice, respectively. Values were normalized 
to 18S to obtain relative expression levels. Results expressed as log2 fold changes between ISC and 
NISC samples demonstrated a down-regulation of the transcripts in both experimental groups. ISC, 
ischemic; NISC, non-ischemic. 
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Supplementary Figure 4: Profiles of leukocytes mobilized to ischemic muscles upon LDIR. 
After surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy or 2.0 Gy in consecutive days. At day 15 post-HLI, 
analysis of CD45+ immune cells that infiltrate ischemic adductor muscles was assessed. (A) 
Representative analysis of hematopoietic CD45+ cells present in ischemic muscle as assessed by 
flow cytometry. Analysis of the accumulation of myeloid CD11b+ cells, and in particular 
macrophages (CD45+CD11b+F4/80+ cells), monocytes (CD45+CD11b+LY6C+F4/80int cells), and 
neutrophils (CD45+CD11b+Ly6Cint). The graphs show numbers of (B) total CD45+ cells; (C) 
monocytes; (D) macrophages and (E) neutrophils, isolated from ISC and NISC adductor muscles. 
Mixed ANOVA followed by Bonferroni post-hoc test was conducted with a within-subject factor of 
ISC and between-subject factor of irradiation. Individual data and means ± SEM (in red) are shown 
from n=4 mice per group; ns, non-significant. ISC, ischemic; NISC, non-ischemic. 
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Supplementary Figure 5: PTK/ZK treatment does not change the effect of LDIR in 
increasing the number of circulating EPCs or the levels of VEGF, PlGF and GCSF in plasma 
after HLI induction. 
After surgical induction of unilateral HLI both hindlimbs of C57BL/6 mice were sham-irradiated or 
irradiated with four daily fractions of 0.3 Gy, in consecutive days and allowed to recover. Two hours 
before each irradiation, ischemic mice were pretreated with PTK/ZK (100mg/Kg) or with the control 
vehicle. (A) Quantitative analysis of EPCs in peripheral blood demonstrated no differences at day 4 
in irradiated mice pretreated with PTK/ZK vs irradiated mice pretreated with the control vehicle. As 
expected a significant increase of EPC at day 4 post-HLI is observed in both experimental groups 
when compared to day 0 pre-HLI or when compared to sham-irradiated mice at day 4. Two-way 
ANOVA was conducted followed by Bonferroni post-hoc test with a between-subject factors of day, 
irradiation and PTK/ZK treatment (n=6 mice per group). Means ± SEM are shown. (B) The 
concentrations of VEGF, PlGF and G-CSF were measured in the plasma, at day 4 post-HLI. The levels 
of VEGF, PlGF and G-CSF are not changed in irradiated mice pretreated with PTK/ZK treatment vs 
irradiated mice pretreated with the control vehicle. Two-way ANOVA was conducted followed by 
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Bonferroni post-hoc test with a between-subject factors of irradiation and PTK/ZK pre-treatment. 
Individual data and means ± SEM are shown (in red) from n=10 or 6 mice per group; ns, non-
significant. ISC, ischemic; NISC, non-ischemic; Pre-HLI, before hindlimb ischemia. 
 
Supplementary Figure 6: In the absence of HLI, LDIR per se do not increase the number of 
circulating EPC. 
Both hindlimbs of C57BL/6 mice were sham-irradiated or irradiated with four daily fractions of 0.3 
Gy, in consecutive days. (A) A schematic illustration of our experimental design. Both hindlimbs 
are irradiated (in orange) or sham-irradiated. (B) Quantitative analysis of EPCs in peripheral blood 
demonstrated no differences at day 4 in irradiated mice and at day 6 in sham-irradiated mice when 
each group is compared to the percentage at day 0, before irradiation. Two-way ANOVA was 
conducted followed by Bonferroni post-hoc test with a between-subject factors of day and 
irradiation. Means ± SEM are shown from n=6 mice per group; ns, non-significant. 
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Supplementary Figure 7: LDIR enhance hypoxia-induced Pgf and Csf3 expression. 
Cells were cultured with or without CoCl2 (150 µM) in normoxia to mimic hypoxic conditions and 
immediately exposed to 0.3 Gy. Eight hours post-irradiation, Pgf and Cxcl12 mRNA was quantified 
by qRT-PCR and 16 hours after Csf3. LDIR significantly increase Pgf and Csf3 mRNA expression. Two-
way ANOVA was conducted followed by Bonferroni post-hoc test with a between-subject factors of 
irradiation and CoCl2 treatment. Individual data represent the fold change in gene expression 
relative to the internal calibrator (−CoCl2) in three independent experiments. Individual data and 
means ± SEM are shown (in red); ***P < 0.001; ns, non-significant. 
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Supplementary Figure 8: The exposure of the ischemic niche to LDIR is critical for the 
increase of cytokines, mobilization of EPCs and collateral formation. 
After surgical induction of unilateral HLI, C57BL/6 mice were irradiated but not in the ischemic niche 
with four daily fractions of 0.3 Gy, in consecutive days. As a control C57BL/6 mice were sham-
irradiated. (A) A schematic illustration of our experimental design. After unilateral HLI 
(represented by a thick brown line), the flow to the ischemic limb is dramatically decreased (in 
blue). Mice are irradiated (in orange) or sham-irradiated but both hindlimbs are not exposed to 
LDIR. (B) Quantitative analysis of EPCs in peripheral blood demonstrated no differences at day 4 in 
irradiated mice and in sham-irradiated mice when compared to the percentage at day d0 pre-HLI.  
Two-way ANOVA was conducted followed by Bonferroni post-hoc test with a between-subject 
factors of day and irradiation (n=6 mice per group). Means ± SEM are shown. (C) The concentrations 
of VEGF, PlGF, G-CSF, and SDF-1α were measured in the plasma, at day 4 post-HLI. The VEGF, PlGF, 
G-CSF and SDF-1α concentrations are not changed by LDIR after HLI induction (n = 10 mice per 
group; for VEGF, PlGF, G-CSF values assumed normal distribution and equal variance and 
independent two-tailed t-test was used; for SDF-1 values not assumed normal distribution, Mann-
Whitney test was used). (D) Data are represented as the percentage of collateral vessel density 
(CVD) increase of the ISC limb relatively to the NISC one. At day 45 post-HLI, no difference in CVD 
upon LDIR was observed. (n=6 mice per group; values assumed normal distribution, equal variance 
and independent two-tailed t-test was used). (C, D) Individual data and means ± SEM (in red) are 
shown; ns, non-significant. Pre-HLI, before hindlimb ischemia; ISC, ischemic; NISC, non-ischemic. 
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Supplementary Figure S9. Confocal and widefield images of the same ten-micron-thick 
section show that green and red fluorescent signals belong to the same cells.  
(A) corresponds to a widefield image acquired with a 20x/0.8 objective on a Zeiss Axiovert 200M 
microscope, with the same acquisition settings that were used for the images in Figure 5C. (B) 
corresponds to the same section imaged on a Zeiss LSM 880 confocal microscope with a 63x/1.4 oil 
immersion objective, with the pinhole set to 1 Airy unit (optical slice thickness = 0.7 micron). Notice 
that even when imaging a single plane, cells show both green and red signals.  
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Supplementary Figure S10. Representative microphotographs of selected organs and 
tissues from sham-irradiated mice and mice irradiated with LDIR. 
No significant changes were observed for liver (A), lung (B) and kidney (C); and no signs of 
immunotoxicity, altered cell distribution/density or neoplasia were seen in lympho-hematopoietic 
organs, namely thymus (D), spleen (E) and bone marrow (F). Hematoxylin and eosin stain; original 
objective magnification 5x (upper panels) and 40x (lower panels).  
 
CHAPTER III 
102 
 
 
 103 
 
 
Chapter IV 
 
Low-dose ionizing radiation promotes neovascularization in 
experimentally induced diabetic mice subjected to hindlimb 
ischemia. 
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Abstract 
Lower limb ischemia is a major health problem. Due to the absence of effective treatment 
in the advanced stages of the disease, limb amputation is required. Recently, we 
demonstrated that low-dose ionizing radiation (LDIR) induces therapeutic 
neovascularization in a pre-clinical model of hindlimb ischemia (HLI). Accordingly to our 
previous data, LDIR induces angiogenesis and arteriogenesis and consequently improves 
blood perfusion in a mice model of HLI. Since almost 50% of the patients with limb ischemia 
are diabetic, in this work we assessed whether LDIR induces neovascularization in response 
to HLI in diabetic mice. Our results suggest that LDIR promotes blood perfusion and 
increases both capillary and collateral densities in diabetic ischemic mice. However, further 
studies are needed to propose the use of LDIR as an innovative pro-angiogenic strategy in 
the treatment of critical limb ischemia in diabetic patients. 
 
Keywords 
Angiogenesis, Low-doses ionizing radiation, Diabetes, Hindlimb ischemia 
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Introduction 
Peripheral arterial disease (PAD) is characterized by lower limb arterial obstruction due to 
atherosclerosis. From a pathophysiologic perspective, PAD can be classified as functional 
or critical. While the functional ischemia occurs when blood flow becomes insufficient 
during exercise but is normal at rest, the critical one occurs when blood flow is insufficient, 
even at rest, and is typically characterized by the presence of trophic lesions in the feet or 
pain while resting. The prevalence of PAD is increasingly recognized as a health burden 
worldwide. Diabetes, smoking, dyslipidaemia and hypertension are important risk factors 
for PAD. Decreasing these risk factors may improve the prognosis1,2. The severity of the 
symptoms is dependent on the extent of the obstructive process and collateral circulation2. 
It is known that after being diagnosed with PAD, 25% of the patients will have a worsening 
ischemic condition with 5 to 10% progressing to critical limb ischemia (CLI). CLI patients 
have chronic ischemic rest pain, ulcers or gangrene. It is the end-stage of PAD and occurs 
when blood flow and distal perfusion pressure are insufficient to satisfy the nutritive needs 
of the limb at rest. CLI is associated with endothelial dysfunction, white blood cell activation 
and inflammation2-4. The primary goals of the treatment of CLI are to relieve ischemic pain, 
heal ulcers, prevent limb loss, improve patient function and quality of life and prolong 
overall survival. However, approximately 20%–30% of patients with CLI can not be treated 
with conventional techniques and still require amputation5. Currently, amputation 
continues to be the recommended solution to the disabling symptoms, even when 
associated with morbidity and mortality2,3.  
 
Almost 50% of the patients with limb ischemia have diabetes and this factor increases 
approximately 3- to 5-fold the risk of PAD6. Furthermore, the duration of diabetes and use 
of insulin are associated with increased risk. PAD is more aggressive in patients with 
diabetes than in non-diabetic ones. This finding is probably due to diabetes-associated 
sensory neuropathy, microangiopathy, and infection, as well as a specific pattern of PAD 
affecting more-distal arteries with fewer possibilities for revascularization. The need for a 
major amputation is 5 to 10 times higher in patients with diabetes than in individuals 
without diabetes2. In patients with CLI, progression to gangrene occurs in 40% of diabetics 
when compared to 9% of non-diabetic patients7. Further, limb salvage rates in diabetic 
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patients with CLI have been reported to be lower than in non-diabetic ones, being diabetes 
an independent risk factor for postoperative amputation and complications in CLI2.  
Diabetes is a metabolic disorder of multifactorial etiology characterized by chronic 
hyperglycemia and changes in the metabolism of carbohydrates, lipids and proteins, 
resulting in absolute or relative impairment of insulin secretion and/ or reduction of its 
biological activity8. This disease is associated with a marked impairment in collateral 
formation. However, angiogenesis is markedly increased in several vascular beds in this 
disease, particularly in retina. This pathological angiogenesis is linked to an excess of 
growth factors production, such as VEGF. Diabetes is also correlated with peripheral 
neuropathy and decreased resistance to infection, which leads to an increased risk of foot 
ulcers and infections2,8. We previously showed that LDIR (lower or equal to 0.8 Gy) induces 
a pro-angiogenic phenotype in ECs in vitro, and promote angiogenesis in vivo during 
regeneration9. Moreover, we recently found that 0.3 Gy, administered during 4 
consecutive days, induces angiogenesis and collateral development and thereby improves 
blood perfusion in experimentally induced hindlimb ischemia (HLI)10. In the present work, 
we aim to demonstrate that LDIR also promotes neovascularization in diabetic mice after 
HLI induction. The obtained results may have the potential to propose an innovative 
strategy using LDIR for pro-angiogenic therapy, which could provide a significant 
contribution to the management of CLI disease. 
 
 
 
 
 
  
CHAPTER IV 
108 
Methods 
Study Approval 
All animal experiments were performed according to EU regulations and approved by the 
Animal Ethics Committee of Instituto de Medicina Molecular (iMM) and by the Direção 
Geral de Alimentação e Veterinária (DGAV; license number 023861/2013). The animal 
facility of iMM complies with the Portuguese law for the use of laboratory animals 
(Decreto-Lei 113/2013); and follows the European Directive 2010/63/EU and the FELASA 
(Federation of European Laboratory Animal Science Associations) guidelines and 
recommendations concerning laboratory animal welfare. 
 
Mice and Reagents 
Eleven-week-old C57BL/6 female mice, purchased from Charles River Laboratories, Spain, 
were used in all HLI experiments. Mice were group-housed in filter-top cages under 
controlled conditions (22±2°C; 12h light/12h dark cycle) and with ad libitum access to water 
and chow.  
Briefly, for the HLI procedure and in vivo imaging, animals were anesthetized by 
intraperitoneal (i.p.) injection with a mixture of ketamine (75 mg/Kg BW; Imalgene1000, 
Merial, France) and medetomidine (1 mg/Kg BW; Domitor, OrionPharma, Espoo, 
Finland). The anaesthesia was reverted with atipamezole (5mg/kg BW, i.p.; Antisedan, 
OrionPharma). Postoperatively, analgesia was administered for pain relief purposes 
(buprenorphine 100 μl/15-30 g BW q8-12 h; Bupaq, RichterPharma AG,Wels, Austria ) 
and the animals were closely monitored until the end of the experiments. Mice were 
euthanized by cervical dislocation. 
 
Diabetes Induction  
Streptozotocin (STZ) (50 mg/Kg) (Sigma) was administrated daily by i.p. injection during 5 
consecutive days and glucose levels were measured 7 days after. Mice with glucose levels 
above 300 mg/dL were considered diabetic. In some experiments (collateral and capillary 
density at 30 days post-HLI), glucose levels were controlled with administration of 1U of 
Insulin Glargine (Lantus Solostar 5064571)11,12. 
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HLI Model 
A surgical procedure was performed to induce unilateral HLI in the mice. Briefly, an incision 
in the skin overlying the thigh of the right hindlimb of each mouse was made and the distal 
external iliac artery and the femoral artery and veins were ligated and excised. The vein 
was ligated both to increase the severity of the ischemia as well as to increase the technical 
reproducibility of the model, since isolation of the femoral artery alone often results in 
tearing of the vein and consequent hemorrhage.  Animals were kept on a 37°C heating pad 
during surgery and recovery period. 
 
Irradiation 
The radiotherapy plan was devised on a dedicated 3D treatment planning system (XiO, 
Elekta) using an isocentric dose distribution of two opposite fields (0°, 180°) at 6 MV photon 
energy, normalized to a reference point. Ionizing radiation was delivered, at room 
temperature, using a linear accelerator that produces X-rays photon beam (Synergy S, 
Elekta) operating at a dose rate of 500 MU/min. 
Anesthetized mice were transferred to an acrylic phantom in order to achieve the adequate 
thickness to improve homogeneity during the radiation therapy. A computed tomography 
scan (Somatom Sensation, Siemens) was performed and a volumetric acquisition was 
carried out. Acquired images were reconstructed with axial slices of 2 mm width, and cross 
sectional data was transferred to the image processing system work station for contouring 
the planning target volume. 
A 0.6 cm3 PTW farmer ionizing chamber, connected to UNIDOS electrometer, was used to 
validate the IR doses calculated by the treatment planning system (TPS), according to the 
IAEA TRS-398 protocol. We obtained, in average, differences lower than 2% between the 
experimental and the XiO TPS dose values. The irradiation field included mice entire legs 
(pelvic girdle down to the feet) or the upper (above hip) part of the mouse body with a 
single-daily dose of 0.3 Gy administered for four consecutive days, starting 12 hours after 
ischemia induction.  Control mice were sham-irradiated (0.0 Gy) following the same 
procedure as for the irradiated experimental groups. The irradiation procedure was 
performed in a non-blinded manner. During this protocol the mice were anesthetized. 
  
CHAPTER IV 
110 
Laser-Doppler Perfusion Imaging 
The laser-Doppler perfusion imager (MoorLDI-V6, Moor Instruments Ltd, Axminster, UK) 
was used to assess limb perfusion. Hair was removed one day before laser Doppler analysis 
using an electrical shaver followed by depilatory cream. Blood flow was measured both in 
the ischemic and non-ischemic legs, before HLI induction (pre-HLI), immediately post-HLI 
(post-HLI), and at days 7, 15 and 21 post-HLI (d7 Post-HLI, d15 Post-HLI and d21 Post-HLI, 
respectively). According to the analysis performed immediately post-HLI, mice were 
randomized assuring an equal reduction of blood flow in the different experimental groups. 
Color-coded images of tissue perfusion were recorded: poor or no perfusion was displayed 
as darkblue, and the highest perfusion level was displayed as red. Mean flux values were 
calculated using the Moor LDI V5.3 image processing software. To account for variables, 
such as temperature and ambient light, blood perfusion was expressed as the ratio of 
ischemic to non-ischemic limb. The mice were kept on a 37°C heating pad to reduce heat 
loss during measurements.   
 
Immunohistochemistry (IHC) and Capillary Density Analysis 
Mice were sacrificed at day 30 post-HLI. The gastrocnemius muscle of both legs were 
harvested, placed in transverse orientation on a small cork disc with the help of 10% 
tragacanth (Sigma, Steinheim, Germany), snap frozen in liquid nitrogen cooled isopentane 
and stored at -80°C until sectioned. Seven-micrometer thick sections were cut on a cryostat 
(Leica CM 3050S, Nussloch, Germany), mounted on glass slides (Menzel-Glaser Super frost® 
Plus; Thermo Scientific, Braunschweig, USA) and then processed to IHC to stain ECs with 
anti-CD31 antibody (Pharmingen). After fixation in acetone, for 10 minutes, hydrogen 
peroxidase (0.3% diluted in methanol) was added, for 30 minutes, followed by 2 washes in 
PBS, for 10 minutes. Blocking solution (5% rabbit serum in PBS) was applied, for 30 minutes, 
and then slides were incubated, for 1 hour, with rat monoclonal antibody against mouse 
CD31 at 1:500, diluted in PBS-1% BSA. After 3 washes in PBS, for 30 minutes, a secondary 
biotinylated rabbit anti-rat IgG antibody (Vectastain ABC kit; Vector Laboratories, Inc, 
Burlingame, CA) was added at 1:200 in PBS-1% BSA plus 5% rabbit serum, for 30 minutes. 
Washes were performed as before and labeled the avidin-conjugated peroxidase complex 
(Vector Laboratories, Inc) was used for color development, according to the manufacturer’s 
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recommendations. After PBS washing (3 times of 5 minutes each), DAB peroxidase 
substrate kit (Vector Laboratories, Inc) was added, for 5 minutes, to localize the immune 
complexes. The sections were counterstained with Harri's Hematoxylin solution (Bio-
Optica, Milan, Italy), for 10 seconds, to visualize nuclei and then mounted with Entellan 
(Merck Millipore). Omission of the primary antibody was run in parallel as negative control. 
All procedure was performed at room temperature. Tissue samples were observed with a 
Leica DM2500 upright brightfield microscope (Leica Microsystems,) using a 10X objective 
and images acquired with a digital camera Leica DFC420 (Software Leica FireCam version 
3.4.1;). Capillary densities, i.e. number of capillaries per number of muscle fibers, were 
measured in 2 sections with 200 µm apart. In each section, 4 distinct anatomical areas were 
measured using the ImageJ1.48 software.   
 
Contrast Agent Perfusion and Diaphonization 
Thirty days post-HLI induction, when mice were well stabilized from the ischemic injury, 
they were deeply anesthetized and the torso and limbs were shaved. A medial thoracotomy 
was performed to expose the heart, after which a needle (26 Gauge), attached to an 
automatic injector, was introduced in the left ventricle. An incision was performed in the 
right atrium to allow venous drainage. Mice were primarily perfused with heparinized 
serum (Braun) (3000 IU/L) until the blood was completely removed from circulation. A 
vasodilatation mixture of adenosine (3.7 µmol/L) and papaverine (11.8 µmol/L) was 
subsequently administered, for 2 minutes, just before the contrast agent, which consisted 
of a mixture of barium sulfate (50%) and gelatin (5%). This solution was kept warm until 
the injection time to avoid thickening. Contrast agent was perfused manually until the feet 
blanched. Immediately after the injection, mice were transferred to a cold chamber to 
allow the solidification of the contrast agent. All the solutions were injected with a 
perfusion rate of 0.01 cm3/s. Then, the skin of each mouse was removed from the lower 
body and diaphonization was performed by using a modified version of Spalteholz 
technique. Briefly, mice were fixated, decalcified, whitened, washed, dehydrated by freeze 
substitution and placed into a vacuum pump with Spalteholz solution (benzyl benzoate and 
methyl salicylate), until transparency was acquired. Diaphonization allows the visualization 
of effective lumen diameter, vessel angulation and emergence position.  
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Collateral vessels quantification 
In order to achieve a homogenous density between the tissues and the media, with minimal 
absorption or reflection of light, mice were kept in Spalteholz solution during image 
acquisition. Mice entire limbs were photographed in a magnifier with a light source. After 
acquisition, images were aligned and stitched together using Adobe Photoshop CS6 and 
entire limb photographs were obtained. Collateral vessels were manually segmented by 
highlighting, using Adobe Photoshop CS6. According to Longland’s definition, collateral 
vessels were considered a defined stem-, mid- and re-entrant zone. According to this 
definition, collateral vessels with a diameter between 20 and 300 µm were included in our 
quantification, excluding femoral, saphenous and popliteal arteries and all venous 
structures. Since arteriogenesis primarily occurs around the occluded blood vessel 
segment, the region of interest (ROI) in every mouse was in the same anatomic region as 
in the adductor, surrounding and bellow the surgical occlusion. Collateral vessel density 
(CVD) was quantified in equivalent ROIs corresponding to 20% of the total limb area. The 
CVD was calculated as the ratio between the vascular and the ROI areas. All density 
measurements were performed using ImageJ® software. To exclude variations in the 
anatomy, perfusion or diaphonization procedures, the CVD value of the non-ischemic limb 
for each mouse was assumed to correspond to 100%. According to this assumption, the 
CVD percentage in the ischemic limb was calculated relatively to the non-ischemic one. The 
percentage of CVD increase was determined as the difference between the CVD percentage 
among the ischemic and non-ischemic limbs.  
 
Statistics 
Experimental results are shown as the mean ± SEM. Data were analyzed with SPSS 20.0 
software for Windows. Statistical test employed are detailed described in figure legends. 
The different analyses were performed in a blinded manner. 
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Results 
LDIR increase perfusion recovery and capillary and collateral densities in 
diabetic mice 
Diabetes were induced with STZ in order to evaluated the effect of LDIR in the restoration 
of blood flow in a diabetic model. Our preliminary experiments using a diabetic model 
showed that animals presented high glucose levels (600 mg/dL), lost body weight and most 
of them also presented signs of cachexia. No differences between ischemic and non-
ischemic muscles were observed, even for the sham-irradiated group, which suggests that 
capillary density is not increased in response to ischemia in diabetic mice. In order to 
stabilize the glucose levels during the experiments and minimize side effects, insulin 
Gargine was administrated whenever mice presented glucose levels higher than 300 
mg/dL. 
Blood flow was analyzed before and after STZ administration to evaluate whether this 
compound per se modulates blood perfusion. Our results shown that STZ does not affect 
blood flow in mice, since values were similar in both experimental groups (Figure 1A). Then, 
by using a model of HLI, diabetic mice were irradiated or not (sham-irradiated) with daily 
fractions of 0.3 Gy, for four consecutive days and perfusion was measured overtime. As 
shown in Figure 1B and quantified in Figure 1C, a dramatic reduction in blood flow was 
observed in the ischemic limb immediately after surgery, in comparison with the 
contralateral limb, and as expected, a gradual improvement in perfusion was observed 
overtime. Interestingly, the blood flow recovery significantly increased in irradiated 
diabetic mice when compared to sham-irradiated ones at 7, 15 and 21 days post-HLI. These 
results demonstrate a benefit of LDIR in diabetic mice with HLI induction. Subsequently, we 
quantified capillary density and collateral vessel development in hindlimb muscles, since 
blood flow recovery depends on both angiogenesis and arteriogenesis. In order to quantify 
the capillary density, diabetic mice were sacrificed at day 30 post-HLI and gastrocnemius 
muscles were collected. Our results showed that capillary density in irradiated ischemic 
muscles was increased when compared to sham-irradiated ones. Also as expected, sham-
irradiated ischemic muscles showed an increase in capillary density when compared to 
their contralateral non-ischemic muscles (Figure 1D). The CVD was evaluated, at day 30 
post-HLI. Mice were diaphonized and an equivalent ROI, corresponding to 20% of the limb 
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area, was selected for CVD quantification. A greater increase in CVD was observed for the 
ischemic limbs of mice exposed to LDIR, versus the sham-irradiated ones (Figure 1E). 
Noteworthy, no difference in these parameters was seen in non-ischemic muscle, either 
exposed to LDIR or sham-irradiated, showing that irradiation per se does not have an effect 
on resting vasculature.  
 
Figure 1. LDIR increases perfusion recovery, capillary and collateral densities in diabetic 
mice.  
After diabetic and surgical induction of unilateral HLI, both hindlimbs of C57BL/6 mice were sham-
irradiated or irradiated with daily fractions of 0.3 Gy, for four consecutive days, and allowed to 
recover. (A) Representative laser Doppler flow images pre- and post- STZ induction (B) 
CHAPTER IV 
115 
Representative laser Doppler flow images pre-HLI, and at days 0 (d0), 7 (d7), 15 (d15) and 21 (d21) 
post-HLI induction. (C) Quantitative evaluation of blood flow expressed as a ratio of ISC to NISC limb 
demonstrated significantly enhanced limb blood perfusion in irradiated mice vs sham-irradiated 
ones both at days 7 (d7), 15 (d15) and 21 (d21) post-HLI. Changes between groups were assessed 
by two-way repeated measurements ANOVA followed by Bonferroni post-hoc test (n=5 mice per 
group). Means ± SEM are shown. (D) Quantitative analysis revealed increased capillary density 
(capillaries/myocyte) in irradiated ischemic gastrocnemius muscles compared with sham-irradiated 
ischemic ones at day 30 post-HLI. Mixed ANOVA followed by Bonferroni post-hoc test was 
conducted with a within-subject factor of ISC and the irradiation factor between-subject (n=3 mice 
per group).  (E) Data are represented as the percentage of collateral vessel density (CVD) increase 
of the ISC limb relatively to the NISC one. At day 30 post-HLI, irradiated mice presented significantly 
higher CVD increase (%) versus sham-irradiated mice. Unpaired two-tailed t-test was performed. 
Values are represented as means ± SEM (n=3 mice per group). *P < 0.05; ** P < 0.01; HLI, hindlimb 
ischemia; ISC, ischemic; NISC, non-ischemic; Pre-HLI, before hindlimb ischemia; Pre-STZ, before STZ 
administration; post-STZ, after STZ administration. 
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Discussion 
CLI represents the most severe clinical manifestation of PAD. This disease involves a severe 
disturbance of both macro and microcirculation. Patients with diabetes have 3 to 5 times 
increased risk of suffering from PAD. The lack of available medical therapy for patients with 
CLI implies that many patients may face amputation as the sole therapeutic option2. 
Amputation is associated with high morbidity and mortality. Therefore, novel therapies are 
required to treat these patients. Therapeutic angiogenesis aims to induce, augment and 
control the host angiogenic response in order to re-vascularize the ischemic tissues.  
Experimental studies are encouraging, while the randomized controlled clinical trials have 
produced less consistent results13.  
We have previously found that LDIR induces angiogenesis. It promotes EC proliferation and 
migration, accelerating wound healing and thereby inducing angiogenesis in vitro and in 
vivo9. Moreover, recently published results show that LDIR promotes therapeutic 
neovascularization in an experimental model of HLI10. In the present work, we aimed to 
validate these results in a diabetic mice model of HLI. Thus, after surgical induction of 
unilateral ischemia, both mouse hindlimbs were irradiated with daily fractions of 0.3 Gy, 
administered during four consecutive days, and a significant increase of blood perfusion 
and capillary and collateral densities was observed.  
However, it is important to refer that the glucose levels were not stable after inducing 
diabetes by STZ administration. Accordingly, we found that in long term evaluations, it is 
crucial to administrate insulin after diabetes induction in order to prevent glucose levels 
higher than 300 mg/dL and consequently minimize the side effects. Our results also suggest 
that the angiogenic response to HLI is affected by the glucose levels, since mice presenting 
high glucose levels (600 mg/dL) and consequently signs of cachexia, did not show an 
increase in capillary density in response to ischemia. Moreover, independently of insulin 
administration in the course of the experiment, an evaluation of diabetic mice during 4 or 
more weeks is very difficult to achieve due to the high mortality rate observed in this 
experimental model, either with or without the LDIR stimuli or ischemia induction and/or 
recovery. On the other side, the sacrifice of the animals could not be performed before 30 
days post-HLI, since the muscles must be recovered and the putative presence of 
adipocytes that characterize the regenerative phase impedes the measurement of the 
capillary density. Similarly, the assessment of arteriogenesis should only be performed 
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after regeneration, when collateral density is already developed and stabilized. To 
overcome the main limitations of the designed model further studies using a larger number 
of animals are required.  
Overall, we believe that this work has the potential to propose a new strategy for 
angiogenic therapy using LDIR, providing a significant contribution to CLI disease 
treatment, particularly in diabetic patients.  
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Concluding Remarks and Future Perspectives  
The circulatory system is a network of specialized blood vessels that carry oxygen and 
nutrients to the organs and tissues of the body1. Diseases of the vascular system, including 
peripheral, cardiac and cerebrovascular diseases, pose a major health burden2. More than 
25 million people have PAD in Europe and The United Stated and its incidence has been 
increasing3. Particularly, PAD is characterized by the narrowing of blood vessels, which 
leads to impaired blood supply to the organs4. PAD may first exist without symptoms, but 
with further progression it may lead to intermittent claudication and advanced disease is 
characterized by pain at rest and ulceration or gangrene of ischemic tissues5. 
Approximately 1% of patients with PAD presents this advanced state of disease resulting in 
CLI with serious prognosis3. Thus, CLI is considered the “end stage” of PAD6. Furthermore, 
in case of CLI, options for vascular interventions, such as stenting or bypass surgery, 
become limited and amputation of ischemic toes, foot or limbs remains the only option in 
50% of patients with CLI within 1 year, because of insufficient response to treatments5. 
Consequently, the development of alternative therapeutic strategies for these high-risk 
patients is strongly needed.  
The concept of “therapeutic angiogenesis”, which can be induced by the delivery of specific 
proteins, genes or cells to ischemic tissue, offers the possibility of blood flow recovery in 
ischemic limbs. Despite substantial evidence of its efficacy in preclinical studies, as well as 
some promising phase I/II human trials, larger randomized clinical trials of angiogenic 
therapies for CLI have been negative. Moreover, there is insufficient knowledge about 
angiogenic agents, namely regarding dose, frequency of administration and method of 
delivery in patients with CLI7. 
 
Therefore, the present PhD thesis aimed to contribute with new insights into therapeutic 
angiogenesis/neovascularization using LDIR as novel strategy for HLI (Chapter III) as well as 
for diabetes associated with HLI (Chapter IV), using mouse models.  
 
In our first data (Chapter III), we show that LDIR synergized with HLI significantly enhances 
blood perfusion, capillary density in gastrocnemius muscle and collateral vessel 
development. Furthermore, we observe that in vasculature not subjected to ischemic 
injury, capillary and collateral densities in irradiated mice are similar to those found in the 
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sham-irradiated ones, suggesting that in non-pathological conditions LDIR per se does not 
have an effect in vascularization. These data are in agreement with our previous results 
where the inter-ray capillary density was not changed by LDIR after irradiation of an intact 
zebrafish caudal fin8. However, when caudal fin was amputated at mid-fin level, we 
demonstrated that LDIR significantly increases the inter-ray capillary density. According to 
our finding, we may hypothesize that LDIR shifts the angiogenic balance towards activation, 
being this effect dependent of the state of the balance. If in equilibrium, LDIR alone does 
not tip the balance towards angiogenesis. However, if the balance is deregulated by 
ischemia, a daily dose of 0.3 Gy, administered for 4 consecutive days, tilts the balance in 
favor of angiogenesis in a HLI mice model.  
In order to understand which genes were significantly modulated by LDIR, a gene 
expression array was carried out and candidates associated with a pro‐angiogenic response 
were analyzed. Our molecular results showed that the expression of several pro-angiogenic 
genes including, Vegfr2, Vegfr1, Fgf2, Angpt2, Pdgfc, Tgfb2, Hgf and Met were clearly up-
regulated in ECs isolated from mice muscle subjected to HLI, when comparing with the 
contralateral limb exclusively exposed to LDIR. The ability of LDIR to increase the expression 
of the pro-angiogenic genes repertoire in endothelium from the ischemic limb suggests a 
pro-angiogenic response. LDIR modulates the gene expression of molecular mediators 
involved in the angiogenic response. It is described that the activation of VEGFR2 leads to 
a rapid activation of different cellular proteins and consequently to de novo mRNA and 
protein expression of mediators involved in the angiogenic response8. Although some of 
these pro-angiogenic genes are frequently used in clinical trials, only one or two are often 
reported, while here we achieved a “cocktail” of angiogenic factors, which may be a 
therapeutic advantage. 
 
The angiogenic potential of ionizing radiation has already been shown for doses equal to 
or above 2 Gy9,10.  A study from Heissing lab demonstrated an increase in vascular 
regeneration using doses of ionizing radiation between 2-10 Gy through recruitment and 
activation of mast cells9. Moreover, Thanik at al showed that a single dose of 5 Gy delivered 
to an ischemic full-thickness cutaneous flap improves vascularity. This study suggests that 
ionizing radiation creates a stimulus for systemic response leading to pro-angiogenic 
effects10. In addition, we have shown that a lower ionizing radiation dose (0.8 Gy) also 
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improves angiogenesis by promoting EC proliferation and migration, accelerating wound 
healing8. These doses, lower than the conventional ones used in radiotherapy, have been 
particularly used in the treatment of benign diseases, due to the anti-inflammatory 
properties of ionizing radiation11. Doses of 0.5 Gy/fraction are especially efficient at the 
beginning of the inflammatory process, characterized by vasodilatation, edema and 
leukocyte infiltration. Data from inflamed and ischemic tissues show that ischemia per se 
increases the immune CD45+ cell infiltrate. However, in our results exposure to 0.3 Gy 
during four consecutive days significantly inhibited the CD45+ cell accumulation, with 
particular effect on monocytes, macrophages and neutrophils. On the other hand, with 
doses of 2.0 Gy during four consecutive days the total CD45+ accumulation in ischemic 
muscle was still reduced; although numbers of monocytes and macrophages were restored 
but neutrophils were not. These results corroborate previous studies that describe ionizing 
radiation with both pro- and anti-inflammatory properties12. Moreover, these properties 
depend on the dose of ionizing radiation, since LDIR (<1 Gy) reveals anti-inflammatory 
properties while doses higher than 2 Gy exert pro-inflammatory effects13.  
 
Besides the use of ionizing radiation as a potential angiogenic therapy, other strategies 
have emerged. Several years ago, a step forward was taken in the understanding of the 
mechanisms of neovascularization. In 1997, Asahara et al identified a class of bone marrow-
derived circulating EPCs that contribute to vasculogenesis in ischemic tissue. After that, the 
term “therapeutic neovascularization” was no longer restricted to angiogenesis, but 
included postnatal vasculogenesis as well.  EPCs are primitive bone marrow cells with the 
capacity to proliferate, migrate and differentiate into ECs. During the last two decades, 
several studies have demonstrated the capability of EPCs to reduce ischemic damage 
effects14,15. Based on the literature, we also know that EPCs enhance collateral formation16. 
EPC recruitment to sites of arteriogenesis is regulated either by interactions between SDF-
1 and its receptor or by several factors secreted by EPCs, both contributing to collateral 
formation17,18.  Studies from Shintani et al show that cells derived from BMNCs contributed 
to collateral formation, detected by angiography in a rabbit model of HLI 19. 
Our work validates previous studies reporting that EPCs are present in the systemic 
circulation and are augmented in response to ischemic damage20,21. Our results also show 
that LDIR, synergistically with HLI, enhances the response of EPCs. It is known that the 
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mobilization of EPCs involves a complex cytokine system. In this way, our results confirm 
that, in response to HLI induction, the concentration of VEGF, PIGF and G-CSF is significantly 
increased in the plasma upon LDIR exposure. This cytokine gradient contributes to the 
mobilization and incorporation of EPCs into ischemic tissues after LDIR exposure and may 
explain the increase in collateral density observed in our work. However, in the absence of 
ischemia, LDIR per se does not induce that effect, suggesting that the pre-existence of an 
ischemic tissue/damage is critical for the mobilization of EPCs upon irradiation. The use of 
EPCs has also been successfully tested in other ischemic diseases. Jackson et al 
demonstrated the incorporation of labeled EPCs in regions of myocardial infarction and22 
Grant et al also demonstrated that the recruitment of EPCs to sites of ischemic injury plays 
a significant role in neovascularization using a mouse model of retinopathy23. 
Moreover, the use of EPCs-based therapies in patients affected by PAD and/or CLI emerged 
as a new approach for the treatment of ischemic conditions. In this context, results of 
several clinical studies have rapidly demonstrated the beneficial effect of autologous BM-
MNC transplantation to patients affected by ischemic diseases14,24.  
 
Nevertheless, for the success of pro-angiogenic therapy, it is essential that long-term safety 
data becomes available. Thus, experimental therapies must be administered with safety 
monitoring. Some aspects related with the impact of angiogenesis on physiological or 
pathological processes and the specific adverse effects associated with each therapy should 
be considered25. In this way, we assessed the potential toxicological effects of LDIR, and no 
significant impact on the morbidity and mortality of the mice was observed after a 52-week 
follow-up study. 
 
To complement the research work developed in Chapter III, we evaluated the potential of 
LDIR in promoting neovascularization after HLI in diabetic mice.  
The discordance between the promising preclinical studies and the disappointing clinical 
trials in angiogenic therapies may be due to problems with the animal model. The mice 
model used in these studies does not totally resemble the human pathology, since patients 
with PAD frequently have additional diseases/risk factors (such as cardiovascular 
conditions, diabetes, hypertension, tobacco). Thus, the addition of at least one of these 
factors to the animal model of HLI will have a great impact in the study of PAD, better 
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mimicking this disease. Diabetes, which is a very common disease in patients with PAD, is 
known to impair angiogenesis. Accordingly, our work shows that LDIR synergized with HLI 
significantly enhance blood perfusion, capillary density in gastrocnemius muscle and 
collateral vessel development in diabetic mice. However, regarding the use of a diabetic 
model, STZ administration for diabetes induction and associated problems together with 
animal welfare will lead us, in the future, to look for a better animal model of diabetes, 
namely transgenic mice. Also, we believe it is crucial to further validate our experimental 
work by increasing the number of animals per group. 
 
In summary, this research work proposes a model of enhanced and sustained angiogenesis 
induction by in situ LDIR administration as a promising therapeutic approach for ischemic 
diseases. LDIR applied as one daily dose of 0.3 Gy, administered for four consecutive days, 
acts synergistically with the ischemic injury, exacerbating the local pro-angiogenic 
response. Our results suggest that this is achieved through (i) increased capillary density 
accompanied by an up-regulation of several pro-angiogenic target genes in ECs localized in 
the gastrocnemius muscles, a process that is dependent on VEGF signaling and (ii) the 
mobilization and recruitment of EPCs by increasing the concentrations of VEGF, PIGF and 
G-CSF, that may explain the collateral density increase in the ischemic limb leading to blood 
perfusion improvement. We also found that, in response to HLI induction, 0.3 Gy applied 
during four consecutive days significantly promote blood perfusion, capillary and collateral 
vessel densities in diabetic mice. Therefore, our data suggest that LDIR may have clinical 
use in the treatment of CLI, particularly in the case of diabetic patients. Additionally, we 
have an ongoing exploratory clinical trial to determine the clinical and molecular effects of 
LDIR in “non-option” CLI patients. The success of this clinical trial will lead to the 
development of new trials to propose a novel and effective therapeutic tool with 
worldwide impact to PAD.    
 
Overall, the present PhD work improves the knowledge on the biological effects of LDIR, in 
a context of HLI and diabetes, and proposes an innovative and non-invasive strategy for 
pro-angiogenic therapy using LDIR. This could provide a significant contribution to the 
management of CLI disease, which will be further corroborated by the ongoing clinical trial. 
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